Bibliografía

1. Scottish Intercollegiate Guidelines Network. Management of diabetes. 2010.
2. National Institute for Health and Clinical Excellence. The guidelines manual. London.
3. Bertoli M, Alarcón G. Epidemiology of Systemic Lupus Erythematosus. In: Systemic Lupus Erythematosus, a companion to Rheumatology. Mosby-Elsevier: Philadelphia, 2007, pp 1–18.
4.Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the general population of Spainw: results from a national survey. Ann Rheum Dis 2001; 60:1040–1045.
5. Carmona L, Laffon A, Ballina J, Gabriel R. Estudio EPISER: Prevalencia de las enfermedades reumáticas en la población española. Metodología, resultados del reclutamiento y características de la población. España, 2001.
6. Rúa-Figueroa I, Erausquin C. Factores asociados a la mortalidad del lupus eritematoso sistémico. Semin la Fund Española Reumatol 2008; 9:219–234.
7. Bernatsky S, Boivin JCF, Joseph L, Manzi S, Ginzler E, Gladman DD et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2550–2557.
8. McElhone K, Abbott J, Teh L. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006; 15:663–643.
9. Zink A, FischerCBetz R, Thiele K, Listing J. Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the national database of the German Collaborative. Lupus 2004; 13:529–536.
10. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69:1269–1274.
11. Anders HCJ, Appel GB. Lupus nephritis:Implications of the new ACR lupus nephritis guidelines. Nat Rev Nephrol 2012; 8:500–501.
12. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERACEDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71:1771–82.
13. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera R et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011; 10:383–388.
14. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. 2007.
15. Calvo-Alén J, Silva-Fernández L, Úcar-Angulo E, Pego-Reigosa JM, Olivé A, Martínez-Fernández C et al. Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. 2013; 9:281–296.
16. Grupo de trabajo de implicación de pacientes en el desarrollo de GPC. Implicación de Pacientes en el Desarrollo de Guías de Práctica Clínica: Manual Metodológico. 2010.
17. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311:376–380.
18. The AGREE Collaboration. Appraisal of guidelines for research & evaluation (AGREE) instrument. AGREE II Instrument. Agree Res. Trust. 2001; :1–20.
19. Oxford Centre for Evidence based Medicine. Oxford Levels of Evidence and Grades of Recommendation. 2009.
20. Montori V, Devereaux P, Straus S, Haynes R, Guyatt G. Decision making and the patient. In:Guyatt G, Rennie D, Meade M, Cook D (eds). Users’ Guides to the Medical Literature: A Manual for EvidenceCBased Clinical Practice. McGrawCHill: New York, NY, 2008.
21. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22:1259–1264.
22. Cervera R, Khamashta M a, Font J, Sebastiani GD, Gil A, Lavilla P et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299–308.
23. Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009; 48:542–545.
24. Kang KY, Kwok SCK, Ju JH, Park KCS, Cho CCS, Kim H-Y et al. The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus 2011; 20:989–997.
25. Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61:1065–1070.
26. Mok CC, Mak A, Chu WP, To CH, Wong SN. Long-term Survival of Southern Chinese Patients With Systemic Lupus Erythematosus. Medicine (Baltimore) 2005; 84:218–224.
27. Nossent J, Cikes N, Kiss E, Marchesoni A, Nassonova V, Mosca M et al. Current causes of death in systemic lupus erythematosus in Europe, 2000--2004:relation to disease activity and damage accrual. Lupus 2007; 16:309–317.
28. Chambers S a, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009; 48:673–675.
29. Ruiz-Irastorza G, Egurbide M-V, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164:77–82.
30. Urowitz MB, Gladman DD, Tom BDM, Ibáñez D, Farewell VT. Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus. J Rheumatol 2008; 35:2152–2158.
31. Doria A, Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol 2005; 32:213–215.
32. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, SarziCPuttini P et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119:700–706.
33. Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010; 10:55–60.
34. Pistiner M, Wallace DJ, Klinenberg JR. Lupus erythematosus in the 1980sw: A Survey of 570 Patients. Semin Arthritis Rheum 1991; 21:55–64.
35. Ozbek S, Sert M, Paydas S, Soy M. Delay in the diagnosis of SLE: the importance of arthritis/arthralgia as the initial symptom. Acta Med Okayama 2003; 57:187–190.
36. Costenbader KH, Karlson EW, Mandl L a. Defining lupus cases for clinical studies:the Boston weighted criteria for the classification of systemic lupus erythematosus. J Rheumatol 2002; 29:2545–50.
37. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40:1725.
38. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al. Derivation and validation of Systemic Lupus International Collaborating Clinics Classification Criteria (SLICC) for Systemic Lupus Erythematosus. Arthritis Rheumatol 2012; 64:2677–2686.
39. Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271–1277.
40. Arbuckle MR, McClain MT, Rubertone M V, Scofield RH, Dennis GJ, James J a et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526–1533.
41. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011; 13:R30.
42. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007; 56:2344–2351.
43. Calvo-Alen J, Alarcon G, Burgard S, Burst N, Bartolucci A, Williams H. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol 1996; 23:469–475.
44. James J a, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007; 16:401–409.
45. Ruiz Irastorza G, Espinosa G, Frutos M a, Jiménez Alonso J, Praga M, Pallarés L et al. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (SEN). Rev Nefrol 2012; 32:1–35.
46. Gill JM, Quisel AM, Rocca P V, Walters DT. Diagnosis of systemic lupus erythematosus. Am Fam Physician 2003; 68:2179–2186.
47. Von Feldt J. Systemic lupus erythematosus. Recognizing its various presentations. Postgrad Med 1995; 97:79.
48. Jakes RW, Bae S-C, Louthrenoo W, Mok C-C, Navarra S V, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012; 64:159–168.
49. Alarcón G, Friedman A, Straaton K, Moulds J, Lisse J, Bastian H et al. Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus in Minority populations: Nature vs. Nurture. Lupus 1999; 8:197–209.
50. Thumboo J, Fong K, Chng H, Koh E, Chia H, Leong K et al. The effects of ethnicity on disease patterns in 472 Orientals with systemic lupus erythematosus. J Rheumatol 1998; 25:1299–1304.
51. Font J. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004; 33:217–230.
52. Alonso MD, Llorca J, Martínez-Vázquez F, Miranda-Filloy J a, Díaz de Teran T, Dierssen T et al. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. Medicine (Baltimore) 2011; 90:350–8.
53. Villamin C, Navarra S. Clinical manifestations and clinical syndromes of Filipino patients with systemic lupus erythematosus. Mod Rheumatol 2008; 18:161–164.
54. Vilá LM, Alarcón GS, McGwin G, Friedman a W, Baethge B a, Bastian HM et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 2004; 43:358–363.
55. Hanly JG, Urowitz MB, Sánchez-Guerrero J, Bae SC, Gordon C, Wallace DJ et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007; 56:265–273.
56. Leroux G, Sellam J, Costedoat-Chalumeau N, Le Thi Huong D, Combes a, Tieulié N et al. Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature. Lupus 2008; 17:139–47.
57. Brey RL, Holliday SL, Saklad a R, Navarrete MG, Hermosillo-Romo D, Stallworth CL et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58:1214–1220.
58. Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MCV, Aguirre C. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 2013; 12:410–415.
59. Cerovec M, Aniw B, Padjen I, ikeš N. Prevalence of the American College of Rheumatology classification criteria in a group of 162 systemic lupus erythematosus patients from Croatia. Croat Med J 2012; 53:149–154.
60. Cervera R, Piette J, Font J, Khamashta MA, Shoenfeld Y, Camps T et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019–1027.
61. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid síndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992; 21:275–86.
62. Vianna J, Khamashta M, OrdiCRos J. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96:3–9.
63. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005; 52:4003–4010.
64. Vilá LM, Molina MJ, Mayor a M, Peredo R a, Santaella ML, Vila S. Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus. Lupus 2006; 15:892–898.
65. Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P et al. Systemic lupus erythematosus: clinical and inmunological patterns of disease expression in a cohort of 1000 patients. The European Working Party on Systemic Lupus Erythematosus. Med 1992; 72:113–124.
66. Rúa-Figueroa I, López-Longo F. Registro nacional de pacientes con lupus eritematoso sistémico de la Sociedad Española de Reumatología: objetivos y metodología. Reumatol Clínica 2014; 10:17–24.
67. Ramal LM, López-Nevot M a, Sabio JM, Jáimez L, Paco L, Sánchez J et al. Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients. Lupus 2004; 13:934–940.
68. Antolín J, Amerigo MJ, Cantabrana A, Roces A, Jiménez P. Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients. Subgroup classification of SLE. Clin Rheumatol 1995; 14:678–685.
69. Font J, Pallarés L, Cervera R, López-Soto A, Navarro M, Bosch X et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis 1991; 50:702–705.
70. Font J, Pallarés L, Cervera R, Vivancos J, López-Soto A, Herrero C et al. Systemic lupus erythematosus: a clinical and immunological study of 300 patients. Med Clin (Barc) 1993; 100:601–605.
71. Alonso MD, Martínez-Vázquez F, de Teran TD, Miranda-Filloy JA, Dierssen T, Blanco R et al. Late-onset systemic lupus erythematosus in Northwestern Spain: differences with early-onset systemic lupus erythematosus and literature review. Lupus 2012; 21:1135–1148.
72. Cartella S, Cavazzana I, Ceribelli A, Inverardi F, Tincani A, Franceschini F. Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. Autoimmunity 2013; 46:363–368.
73. Lalani S, Pope J, de León F, Peschken C. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol 2010; 37:38–44.
74. Bertoli AM, Alarcón GS, Calvo-Alén J, Fernández M, Vilá LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum 2006; 54:1580–1587.
75. Pu SJ, Luo SF, Wu YJ, Cheng HS, Ho HH. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus 2000; 9:96–100.
76. Achour A, Mankaï A, Thabet Y, Sakly W, Braham F, Kechrid C et al. Systemic lupus erythematosus in the elderly. Rheumatol Int 2012; 32:1225–1229.
77. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A Disease activity index for lupus patients. Arthritis Rheum 1992; 35:630–640.
78. Bencivelli W, Vitali C, Isenberg D, Smolen J, Snaith M, Sciuto M. lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart. Clin Exp Rheumatol 1991; 10:549–554.
79. Renau a I, Isenberg D a. Male versus female lupus: a comparison of ethnicity, clinical features, serology and outcome over a 30 year period. Lupus 2012; 21:1041–1048.
80. Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19:949–956.
81. Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen J et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol 1998; 17:468–477.
82. Stefanidou S, Benos A, Galanopoulou V, Chatziyannis I, Kanakoudi F, Aslanidis S et al. Clinical expression and morbidity of systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male:female comparison. Lupus 2011; 20:1090–1094.
83. Alonso MD, Martínez-Vázquez F, Riancho-Zarrabeitia L, Díaz de Terán T, Miranda-Filloy J a, Blanco R et al. Sex differences in patients with systemic lupus erythematosus from Northwest Spain. Rheumatol Int 2014; 34:11–24.
84. López P, Mozo L, Gutiérrez C, Suárez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 2003; 12:860–865.
85. García M a, Marcos JC, Marcos a I, Pons-Estel B a, Wojdyla D, Arturi A et al. Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. Lupus 2005; 14:938–946.
86. Molina J, Drenkard C, Molina J, Cardiel M, Uribe O, Anaya J et al. Systemic lupus erythematosus in males A study of 107 Latin American patients. Medicine (Baltimore) 1996; 75:124–130.
87. Feng J-B, Ni J-D, Yao X, Pan H-F, Li X-P, Xu J-H et al. Gender and age influence on clinical and laboratory features in Chinese patients with systemic lupus erythematosus: 1,790 cases. Rheumatol Int 2010; 30:1017–23.
88. The American College of Rheumatology ad hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599–608.
89. Koh WH, Fong KY, Boey ML, Feng PH. Systemic lupus erythematosus in 61 Oriental males. A study of clinical and laboratory manifestations. Br J Rheumatol 1994; 33:339–342.
90. Chang DM, Chang CC, Kuo SY, Chu SJ, Chang ML. The clinical features and prognosis of male lupus in Taiwan. Lupus 1998; 7:462–468.
91. Mongkoltanatus J, Wangkaew S, Kasitanon N, Louthrenoo W. Clinical features of Thai male lupus: an age-matched controlled study. Rheumatol Int 2008; 28:339–344.
92. Meszaros ZS, Perl A, Faraone S V. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry 2012; 73:993–1001.
93. Wekking EM. Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosom Med 1993; 55:219–228.
94. Swaak A, Nieuwenhuis E, Smeenk R. Changes in clinical features of patients with systemic lupus erythematosus followed prospectively over 2 decades. Rheumatol Int 1992; 12:71–75.
95. Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM. Systemic Lupus Erythematosus in Greece. Clinical Features, Evolution and Outcome: a Descriptive Analysis of 292 Patients. Lupus 1993; 2:303–312.
96. Boddaert J, Huong DLT, Amoura Z, Wechsler B, Godeau P, Piette J-C. Late-Onset Systemic Lupus Erythematosus. Medicine (Baltimore) 2004; 83:348–359.
97. Alarcón-Segovia D, Delezé M, Oria C, Sánchez-Guerrero J, Gómes-Pacheco L, Cabiedes J et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Med 1989; 68:353–365.
98. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens. Arch Pathol Lab Med 2000; 124:71–81.
99. James K, Carpenter AB, Cook L, Nakamura RM. Development of the Antinuclear and Anticytoplasmic Antibody Consensus Panel by the Association of Medical Laboratory Immunologists Development of the Antinuclear and Anticytoplasmic Antibody Consensus Panel by the Association of Medical Laboratory Immunol. Clin Vaccine Immunol 2000; 7:436–443.
100. Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002; 117:316–324.
101. The American College of Rheumatology ad hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. Arthritis Rheum 2002; 47:429–433.
102. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002; 47:434–444.
103. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49:399–412.
104. Benito-García E, Schur PH, Lahita R. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 2004; 51:1030–1044.
105. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014; 73:17–23.
106. Zagorov MY, Draganov MM, Alimanska SA, Staykova ND, Stefanov RS, Trayancheva M et al. Indirect immunofluorescent assay for antinuclear antibodies on McCoy-Plovdiv serum-free cell line substrate. Comp Immunol Microbiol Infect Dis 2007; 30:153–162.
107. Marín GG, Cardiel MH, Cornejo H, Viveros ME. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol 2009; 15:325–329.
108. Cabiedes J, Núñez-Álvarez CA. Antinuclear antibodies. Reumatol Clínica 2010; 6:224–230.
109. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LEC. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:191–200.
110. Pazini A, Fleck J, Santos R, Beck S. Clinical relevance and frequency of cytoplasmic and nuclear dense fine speckled patterns observed in ANA-HEp-2. Brazilian J Rheumatol 2010; 50:660–664.
111. Alarcón-Torres I, González-Rodríguez C, Jiménez-Jiménez J, Fernández-Suárez A, Alsina-Donadeu M. Actualización en el manejo de los anticuerpos antinucleares en las enfermedades autoinmunes sistémicas. 2014.
112. Almeida D, Cabrera A, Roces A, García M, Sequera M De, Rodríguez MDC et al. Autoantibody detection with indirect immunofluorescence on HEp-2 cells: starting serum dilutions for systemic rheumatic diseases. Immunol Lett 2011; 140:30–35.
113. González-Buitrago JM, González C. Present and future of the autoimmunity laboratory. Clin Chim Acta 2006; 365:50–7.
114. Tan E, Feltkamp T, Smolen J, Butcher B, Dawkins R, Fritzler M et al. Range of antinuclear antibodies in ‘healthy’ individuals. Arthritis Rheum 1997; 40:1601–11.
115. Tan ENGM, Smolen JS, Dougal JSMC, Butcher BT, Conn D, Dawkins R et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. Arthritis Rheum 1999; 42:455–464.
116. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010; 69:1420–1422.
117. Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T et al. Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 2009; 1173:166–173.
118. Fenger M, Wiik A, Høier-Madsen M, Lykkegaard JJ, Rozenfeld T, Hansen MS et al. Detection of antinuclear antibodies by solidCphase immunoassays and immunofluorescence analysis. Clin Chem 2004; 50:2141–2147.
119. Emlen W, O’Neill L. Clinical significance of antinuclear antibodies. Comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997; 40:1612–1618.
120. Xavier RM, Yamauchia Y, Nakamura M, Tanigawab Y, Ishikurac H, Tsunematsud T et al. Antinuclear antibodies in healthy aging people: a prospective study. Mech Ageing Dev 1995; 78:145–154.
121. Kiuttu J, Hartikainen A, Mäkitalo R, Ruuska P. The outcome of pregnancy in antinuclear antibodyCpositive women. Gynecol Obstet Invest 1994; 37:160–163.
122. Sontheimer R, McCauliffe D, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol 1992; 7:3–52.
123. Li Q-Z, Karp DR, Quan J, Branch VK, Zhou J, Lian Y et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011; 13:R38.
124. Adams B, Mutasim D. The diagnostic value of antinuclear antibody testing. Int J Dermatol 2000; 39:887–892.
125. Altintas A, Ozel A, Okur N, Okur N, Cil T, Pasa S et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis 2007; 24:163–168.
126. Servais G, Karmali R, Guillaume MP, Badot V, Duchateau J, Corazza F. Anti DNA antibodies are not restricted to a specific pattern of fluorescence on HEp2 cells. Clin Chem Lab Med 2009; 47:543–549.
127. Tampoia M, Fontana a., Di Serio F, Maggiolini P, Pansini N. Application of a diagnostic algorithm in autoantibody testing: assessment of clinical effectiveness and economic efficiency. Clin Chim Acta 2003; 333:181–183.
128. Tampoia M, Brescia V, Fontana A, Zucano A, Morrone LF, Pansini N. Application of a Combined Protocol for Rational Request and Utilization of Antibody Assays Improves Clinical Diagnostic Efficacy in Autoimmune. Arch Pathol Lab Med 2007; 131:112–116.
129. Copple SS, Giles SR, Jaskowski TD, Gardiner AE, Wilson AM, Hill HR. Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization. Am J Clin Pathol 2012; 137:825–830.
130. Jaskowski T, Schroder C. Screening for antinuclear antibodies by enzyme immunoassay. Am J Clin Pathol 1996; 105:468–473.
131. Avaniss-Aghajani E, Berzon S, Sarkissian A. Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens. Clin Vaccine Immunol 2007; 14:505–509.
132. Biagini RE, Parks CG, Smith JP, Sammons DL, Robertson SA. Analytical performance of the AtheNA MultiLyte ANA II assay in sera from lupus patients with multiple positive ANAs. Anal Bioanal Chem 2007; 388:613–618.
133. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 2012; 12:97–106.
134. Bossuyt X, Cooreman S, De Baere H, Verschueren P, Westhovens R, Blockmans D et al. Detection of antinuclear antibodies by automated indirect immunofluorescence analysis. Clin Chim Acta 2013; 415:101–106.
135. Bertin D, JourdeCChiche N, Bongrand P, Bardin N. Original approach for automated quantification of antinuclear autoantibodies by indirect immunofluorescence. Clin Dev Immunol 2013. http://downloads.hindawi.com/journals/cdi/2013/182172.pdf (accessed 27 Mar 2015).
136. Murai R, Yamada K, Tanaka M, Kuribayashi K, Kobayashi D, Tsuji N et al. Reconstructing a 3-dimensional image of the results of antinuclear antibody testing by indirect immunofluorescence. J Immunol Methods 2013; 387:312–316.
137. Grossmann K, Roggenbuck D, Schröder C, Conrad K, Schierack P, Sack U. Multiplex assessment of non-organ-specific autoantibodies with a novel microbead-based immunoassay. Cytometry A 2011; 79:118–125.
138. El-Chennawi F a, Mosaad YM, Habib HM, El-Degheidi T. Comparative study of antinuclear antibody detection by indirect immunofluorescence and enzyme immunoassay in lupus patients. Immunol Invest 2009; 38:839–850.
139. Campos-González ID, Viveros ME, Cardiel MH. Utilidad clínica de las pruebas inmunológicas especializadas en reumatología en un hospital de segundo nivel de atención en México. Rheumatol Clínica 2007; 3:110–117.
140. Hahn B. Antibodies to DNA. N Engl J Med 1998; 338:1359–1369.
141. Barbas SM, Ditzel HJ, Salonen EM, Yang WP, Silverman GJ, Burton DR. Human autoantibody recognition of DNA. Proc Natl Acad Sci U S A 1995; 92:2529–2533.
142. Swaak T, Smeenk R. Detection of anti-dsDNA as a diagnostic tool:a prospective study in 441 non-systemic lupus erythematosus patients with anti-dsDNA antibody (anti-dsDNA). Ann Rheum Dis 1985; 44:245–251.
143. Kavanaugh AF, Solomon DH. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002; 47:546–555.
144. Bootsma H, Spronk P, Hummel E, de Boer G, ter Borg E, Limburg P et al. Anti-double stranded DNA antibodies in systemic lupus erythematosus: Detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996; 25:352–359.
145. Riboldi P, Gerosa M, Moroni G, Radice A, Allegri F, Sinico A et al. Anti-DNA antibodies:a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 2005; 38:39–45.
146. Launay D, Schmidt J, Lepers S, Mirault T, Lambert M, Kyndt X et al. Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. Clin Chim Acta 2010; 411:959–964.
147. Avina-Zubieta J, Galindo-Rodríguez G, Kwan-Yeung L, Davis P, Russell A. Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies. Lupus 1995; 4:370–374.
148. Werle E, Blazek M, Fiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus 1992; 1:369–377.
149. Ghirardello A, Villalta D, Morozzi G, Afeltra A, Galeazzi M, Gerli R et al. Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays . An Italian multicentre. Clin Exp Rheumatol 2011; 29:50–56.
150. Tan EM, Smolen JS, McDougal JS, Fritzler MJ, Gordon T, Hardin J a et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol 2002; 29:68–74.
151. Lerner MR, Steitz J a. Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 1979; 76:5495–5499.
152. Aziz K, Faizal A. The role of the clinical immunology laboratory in the diagnosis and monitoring of connective tissue diseases. Saudi Med J 2001; 44:1796–1807.
153. Ward M, Studenski S. Clinical manifestations of systemic lupus erythematosus: identification of racial and socioeconomic influences. Arch Intern Med 1990; 150:849–853.
154. Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002; 11:161–167.
155. Isenberg D, Garton M, Reichlin MW, Reichlin M. Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. Br J Rheumatol 1997; 36:229–233.
156. Arnett F, Hamilton R, Roebber M, Harley J, Reichlin M. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol 1988; 15:1773–1776.
157. Field M, Williams DG, Charles P, Maini RN. Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens. Ann Rheum Dis 1988; 47:820–825.
158. Copple S, Martins T, Masterson C, Joly E, Hill H. Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically. Ann N Y Acad Sci 2007; 1109:464–472.
159. Ptová I Dosta C Becvar R Prevalence of antinucleosome antibodies by enzyme-linked immunosorbent assays in patients with systemic lupus erythematosus and other autoimmune systemic diseases. Ann N Y Acad Sci 2007; 1109:275–286.
160. Carmona-Fernandes D, Santos MJ, Canhão H, Fonseca JE. Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Med 2013; 11:98.
161. Barkhudarova F, Dähnrich C, Rosemann A, Schneider U, Stöcker W, Burmester G-R et al. Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Ther 2011; 13:R20.
162. Ghirardello a, Doria A, Zampieri S, Gerli R, Rapizzi E, Gambari PF. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis 2000; 59:975–81.
163. Rao L, Liu G, Li C, Li Y, Wang Z, Zhou Z et al. Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus. Exp Ther Med 2013; 5:1710–1714.
164. Smith E, Shmerling R. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus 1999; 8:586–595.
165. Cohen A, Reynolds W, Franklin E, Kulka J, Ropes M, Shulman L et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971; 21:643–648.
166. Gibson T, Dibona G. Use of the American Rheumatism Association’s preliminary criteria for the classification of systemic lupus erythematosus. Ann Intern Med 1972; 77:754–756.
167. Johnson SR, Goek O-N, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum 2007; 57:1119–1133.
168. Clough J, Elrazak M, Calabrese L, Valenzuela R, Braun W, Williams G. Weighted criteria for the diagnosis of systemic lupus erythematosus. Arch Intern Med 1984; 144:281–285.
169. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677–86.
170. Romero-Díaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questi. Arthritis Care Res (Hoboken) 2011; 63:S37–S46.
171. Abu-Shakra M, El-Sana S, Margalith M, Sikuler E, Neumann L, Buskila D. Hepatitis B and C viruses serology in patients with SLE. Lupus 1997; 6:543–544.
172. Erdozain J, Egurbide M, Aguirre C. High risk of tuberculosis in systemic lupus erythematosus ? Lupus 2006; 15:232–235.
173. Okamura M, Kanayama Y, Amastu K, Negoro N, Kohda S. Significance of enzyme linked immunosorbent assay ( ELISA ) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of rena histology Ann Rheum Dis 1993; 52:14–20.
174. Hanly JG, Su L, Farewell V, Fritzler MJ. Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. J Immunol Methods 2010; 358:75–80.
175. Barada F, Andrews B. Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum 1981; 24:1236–1244.
176. Janwityanuchit S, Verasertniyom O, Vanichapuntu M, Vatanasuk M. Anti-Sm: its predictive value in systemic lupus erythematosus. Clin Rheumatol 1993; 12:350–353.
177. McCain G, Bell D, Chodirker W, Komar R. Antibody to extractable nuclear antigen in the rheumatic diseases. J Rheumatol 1978; 5:399–406.
178. Yee C-S, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 2003; 42:276–279.
179. Yamane K, Shome G, Akama T, Suzuki H, Matsui Y, Kashiwagi H. Clinical features of patients with mild systemic lupus erythematosus. Scand J Rheumatol 1991; 20:397–405.
180. Yasuma M, Takasaki Y, Matsumoto K, Kodama A, Hashimoto H, Hirose S. Clinical significance of IgG anti-Sm antibodies in patients with systemic lupus erythematosus. J Rheumatol 1990; 17:469–475.
181. Gripenberg M, Teppo A, Friman C. Antibodies to Sm and SS-A demonstrated by enzyme immunoassay. Correlation to clinical manifestations and disease activity in patients with systemic lupus erythematosus. Rheumatol Int 1991; 11:209–2013.
182. Yamamoto A, Amoura Z, Johannet C, Jeronimo A, Campos H, Koutouzov S et al. Quantitative radioligand assays using de novo-synthesized recombinant autoantigens in connective tissue diseases: new tools to approach the pathogenic significance of anti-RNP antibodies in rheumatic diseases. Arthritis Rheum 2000; 43:689–698.
183. Westgeest A, van den Brink H, de Jong J, Swaak A, Smeenk R. Antinuclear antibodies in patients with systemic lupus erythematosus: a comparison of counterimmunoelectrophoresis and immunoblotting. Rheumatol Int 1987; 7:77–82.
184. Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S et al. Distribution and antigen specificity of anti-U1RNP antibodies in patients with. Clin Exp Immunol 1999; 117:383–387.
185. Nishikai M, Okano Y, Mukohda Y, Sato A, Ito M. Serial estimation of anti-RNP antibody titers in systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis. J Clin Lab Immunol 1984; 13:15–19.
186. Su Y, Jia R-L, Han L, Li Z-G. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol 2007; 122:115–120.
187. Kiss E, Lakos G, Szegedi G, Poor G, Szodoray P. Anti-nuscleosome antibody , a reliable indicator for lupus nephritis. Autoimmunity 2009; 42:393–398.
188. Cairns A, McMillan S, Crockard A, Meenagh G, Duffy E, Armstrong D et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 2003; 62:272–273.
189. Cervera R, Vinas O, Ramos-Casals M, Font J, García-Carrasco M, Sisó A et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rh 2003; 62:431–434.
190. Bose N, Wang X, Gupta M, Yao Q. The clinical utility of anti-chromatin antibodies as measured by BioPlex 2200 in the diagnosis of systemic lupus erythematosus versus other rheumatic. Int J Clin Exp Med 2012; 5:316–320.
191. Gutiérrez-Adrianzén O. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-. J Rheumatol 2006; 33:1538–1544.
192. Bonfa E, Golombek S, Kaufman L, Skelly S, Weissbach H, Brot N et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265–271.
193. Hanly JG, Urowitz MB, Su L, Bae S-C, Gordon C, Clarke A et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70:1726–1732.
194. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58:843–853.
195. Haddouk S, Marzouk S, Jallouli M, Fourati H, Frigui M, Hmida YBH et al. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology 2009; 48:953–957.
196. Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology 2002; 41:1357–1366.
197. Watanabe T, Sato T, Uchiumi T, Arakawa M. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: diagnostic and predictive value of longitudinal examination of anti-ribosomal P. Lupus 1996; 5:178–183.
198. Tzioufas AG, Tzortzakis NG, Boki KA, Sakarellos C, Moutsopoulos HM. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 2000; 59:99–104.
199. Massardo L, Burgos P, Martínez M, Pérez R, Calvo M, Barros J et al. Antiribosomal P protein antibodies in Chilean SLE patients: no association with renal disease. Lupus 2002; 11:379–383.
200. Karassa FB, Afeltra A, Ambrozic A, Chang D-M, De Keyser F, Doria A et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54:312–324.
201. West SG, Emlen W, Wener MH, Kotzin BL. Prospective Study on the Value of Diagnostic Tests. Am J Med 1995; 99:153–163.
202. Ghirardello A, Caponi L, Franceschini F, Zampieri S, Quinzanini M, Bendo R et al. Diagnostic Tests for Antiribosomal P Protein Antibodies: A Comparative Evaluation of Immunoblotting and ELISA Assays. J Autoimmun 2002; 19:71–77.
203. Gillis JZ, Panopalis P, Schmajuk G, Ramsey-Goldman R, Yazdany J. Systematic review of the literature informing the systemic lupus erythematosus indicators project: reproductive health care quality indicators. Arthritis Care Res (Hoboken) 2011; 63:17–30.
204. Shi W, Gordon S, Chesterman C, Krilis S, Chong B. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20:231–236.
205. Martínez-Berriotxoa A, Ruiz-irastorza G, Egurbide M, Garmendia M, Erdozain JG, Villar I et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2007; 16:810–816.
206. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012; 64:504–512.
207. Tomer Y, Viegas O, Swissa M, Koh S, Shoenfeld Y. Levels of lupus autoantibodies in pregnant SLE patients: correlations with disease activity and pregnancy outcome. Clin Exp Rheumatol 1996; 14:275–280.
208. Royal College of Obstetricians and Gynaecologists (RCOG). The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. Royal College of Obstetricians and Gynaecologists: London (UK), 2011.
209. American College of Obstetricians and Gynecologists (ACOG). Antiphospholipid syndrome. American College of Obstetricians and Gynecologists: Washington (DC), 2011.
210. Finnish Medical Society Duodecim. Blood transfusion: indications, administration and adverse reactions. In: Wiley Interscience, John Wiley & Sons (eds). Evidence-Based Medicine. Helsinki, Finland, 2008.
211. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta M a, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012; 10:2512–2518.
212. Sullivan K, Wisnieski J, Winkelstein J, Louie J, Sachs E, Choi R. Serum complement determinaton in patients with quiescent systemic lupus erythematosus. J Rheumatol 1996; 23:2063–2067.
213. Mollnes TE, Haga H, Brun JG, Nielsen EW, Bergh K, Sjo A et al. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology 1999; 38:933–940.
214. Amezcua-Guerra L, Springall R, Arrieta-Alvarado A, Rodríguez V, Rivera-Martínez E, Castillo-Martínez D et al. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin Lab 2011; 57:607–613.
215. Ho a, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:2350–2357.
216. Gunnarsson I, Rönnelid J, Huang YH, Rogberg S, Nilsson B, Lundberg I et al. Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Brithish J Rheumatol 1997; 36:32–37.
217. Sjoholm A, Martensson U, Sturfelt G. Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus. J Rheumatol 1997; 24:871–878.
218. Siegert C, Daha M, Westedt M, van der Voort E, Breedveld F. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 1991; 18:230–234.
219. Becker GJ, Waldburger M, Hughes GR V, Pepys MB. Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 1980; 39:50–52.
220. Stojan G, Fang H, Magder L, Petri M. Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. Lupus 2013; 22:827–834.
221. Vilá LM, Alarcón GS, Mcgwin G, Bastian HM, Fessler BJ, Jr GM et al. and damage accrual . Systemic Lupus Erythematosus in a Multiethnic Cohort (LUMINA): XXIX . Elevation of Erythrocyte Sedimentation Rate Is Associated with Disease Activity and Damage Accrual. J Rheumatol 2005; 32:2150–2155.
222. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology 2000; 39:1316–1319.
223. Ng WL, Chu CM, Wu a KL, Cheng VCC, Yuen KY. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM 2006; 99:37–47.
224. Ciruelo E, de la Cruz J, López I, Gómez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39:2028–2034.
225. Illei G, Takada K, Parkin D. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppresive therapy. Arthritis Rheum 2002; 46:995–1002.
226. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50:2559–2568.
227. Moroni G, Quaglini S, Maccario M. Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50:2047–2053.
228. Lundberg I, Nyman U, Pettersson I, Hedfors E. Clinical manifestations and anti-(U1) snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients. Rheumatology 1992; 31:811–817.
229. Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R. Prevalence and Clinical Correlation of Anti-Phospholipid – Binding Protein Antibodies in Anticardiolipin-Negative Patients With Systemic Lupus Erythematosus and Women With Unexplained. Arch Pathol Lab Med 2005; 129:61–68.
230. Tubach F, Hayem G, Marchand J, Weber M, Palazzo E, de Bandt M et al. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000; 27:1437–1443.
231. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93:1–6.
232. Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75:456–459.
233. Horbach D, van Oort E, Donders R, Derksen R, de Groot P. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76:916–924.
234. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001; 114:647–654.
235. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T et al. Association between the Prevalence of Antibodies to 2 -Glycoprotein I, Prothrombin, Protein C, Protein S, and Annexin V in Patients with Systemic Lupus Erythematosus and Thrombotic and Thrombocytopenic Complications. Clin Chem 2001; 47:1008–1015.
236. Muñoz-Rodríguez F, Reverter J, Font J, Tàssies D, Cervera R, Espinosa G et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 2000; 85:632–637.
237. Palosuo T, Virtamo J, Haukka J, Taylor P, Aho K, Puurunen M et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men--a nested case-control study. Thromb Haemost 1997; 78:1178–1182.
238. Forastiero R, Martinuzzo M, Pombo G, Puente D, Rossi A, Celebrin L et al. A prospective study of antibodies to 2-glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 2005; 3:1231–1238.
239. Hind C, Ng S, Feng P, Pepys M. Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus. Ann Rheum Dis 1985; 44:260–261.
240. Zein N, Ganuza C, Kushner I. Significance of serum C-reactive protein elevation in patients with systemic lupus erythematosus. Arthritis Rheum 1979; 22:7–12.
241. Bertsias G, Cervera R, Boumpas D. Systemic lupus erythematosus: pathogenesis and clinical features. In: BMJ Group (ed). EULAR Textbook of rheumatic diseases. London (UK), 2012, pp 476–505.
242. Bertsias G, Ioannidis JP a, Boletis J, Bombardieri S, Cervera R, Dostal C et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67:195–205.
243. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2011; 69:1269–1274.
244. Bertsias GK, Ioannidis JP a, Aringer M, Bollen E, Bombardieri S, Bruce IN et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69:2074–2082.
245. Nikpour M, Gladman DD, Ibáñez D, Harvey PJ, Urowitz MB. Variabiity over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. Arthritis Res Ther 2010; 12:1–9.
246. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology 2004; 43:7–12.
247. Gladman DD, Ibáñez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol 2013; 40:630–633.
248. Gladman DD, Urowitz MB, Rahman P, Ibáñez D, Tam L-S. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1955–9.
249. Walz L, Gladman D, Urowitz M. Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares. J Rheumatol 1994; 21:2239–2241.
250. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010; 37:1822–1827.
251. American College of Rheumatology Ad Hoc Committee on systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999; 42:1785–1795.
252. Gladman DD, Hirani N, Ibañez D, Urowitz MB. Clinically Active Serologically Quiescent Systemic Lupus Erythematosus. J Rheumatol 2003; 30:1960–1962.
253. Gheita TA, El-Gazzar II, Azkalany G, El-Fishawy HS, El-Faramawy A. High-sensitivity C-reactive protein (hs-CRP) in systemic lupus erythematosus patients without cardiac involvement; relation to disease activity, damage and intima-media thickness. Egypt Rheumatol 2012; 34:147–152.
254. Barnes E V, Narain S, Naranjo A, Shuster J, Segal MS, Sobel ES et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity clinica presentation and implications for cardiovascular risk. Lupus 2005; 14:576–582.
255. Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38:41–54.
256. Lee S, Singh S, Magder LS, Petri M. Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 2008; :114–123.
257. Bertoli A, Vilá L, Reveille J, Alarcón G. Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus. Ann Rheum Dis 2008; 67:500–504.
258. Banerjee S, Sarkar RN, Mullick OS, Bhattacharyya K, Das A, Bhattacharya R et al. A cross-sectional study to assess the association of systemic lupus erythematsous disease activity with levels of high sensitivity C-reactive protein. Indian J Rheumatol 2013; 8:61–64.
259. Mok C, Birmingham D. High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res 2013; 65:441–447.
260. Pradhan V, Rajadhyaksha A, Patwardhan M, Surve P, Dhavale N, Pandit P et al. High sensitivity C-reactive protein (hsCRP): Association with clinical subsets in systemic lupus erythematosus (SLE) patients from Western India. Indian J Rheumatol 2013; 8:65–67.
261. Sjöwall C, Bengtsson A a, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004; 6:R87–R94.
262. Valentijn R, van Overeem H, Hazevoet H, Hermans J, Cats A, Daha M et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1985; 28:904–913.
263. Ng KP, Manson JJ, Rahman A, Isenberg D a. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55:900–904.
264. Rekvig OP, van der Vlag J, Seredkina N. Review: antinucleosome antibodies: a critical reflection on their specificities and diagnostic impact. Arthritis Rheumatol 2014; 66:1061–1069.
265. Thudi A, Yin SU, Wandstrat AMYE, Li Q, Olsen NJ. Vitamin D Levels and Disease Status in Texas Patients With Systemic Lupus Erythematosus. Am J Med Sci 2008; 355:99–104.
266. Yeap SS, Othman AZ, Zain AA, Chan SP. Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids. Int J Rheum Dis 2012; 15:17–24.
267. Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum 2013; 65:1865–1871.
268. Kingsmore S, Thompson J, Crockard A, Todd D, McKirgan J, Patterson C et al. of circulating immune complexes containing IgG, IgM, IgA and IgE by flow cytometry:correlation with disease activity in patients with systemic lupus erythematosus. J Clin Lab Immunol 1989; 30:45–52.
269. Inman R, Fong J, Pussell B, Ryan P, Hughes G. The C1q binding assay in systemic lupus erythematosus. Arthritis Rheum 1980; 23:1282–1286.
270. Calvo-Alén J, Silva-Fernández L, Úcar-Angulo E, Pego-Reigosa JM, Olivé A, Martínez-Fernández C et al. SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatol Clin 2013; 9:281–96.
271. Vitali C, Bencivelli W, Isenberf D, Smolen J, Snaith M, Sciuto M et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the. Clin Exp Rheumatol Rheumatol 1991; 10:541–547.
272. Isenberg D, Bacon P, Bombardier C, Gladman D, Goldsmith C, Kalunian K et al. Criteria for assessing disease activity in systemic lupus erythematosus. J Rheumatol 1989; 16:1395–1396.
273. Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D et al. Randomized Clinical Trials and Longitudinal Observational Studies in Systemic Lupus Erythematosus: Consensus on a Preliminary Core Set of Outcome Domains J Rheumatol 1999; 26:504–507.
274. Fortin P, Abrahamowicz M, Clarke A, Neville C, Du Berger R, Fraenkel L et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000; 27:1421–1428.
275. Arce-Salinas A, Cardiel M. Validity of retrospective disease activity assessment in systemic lupus erythematosus. J Rheumatol 1996; 23:846–849.
276. Uribe A, Vilá L, McGwin G, Sánchez M, Reveille J, Alarcón G. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate. J Rheumatol 2004; 31:1934– 1940.
277. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550–2558.
278. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996; 55:756–760.
279. Isenberg D, Rahman A, Allen E, Farewell V, Akil M, Bruce IN et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005; 44:902–906.
280. Yee C-S, Farewell V, Isenberg D, Rahman A, Teh L-S, Griffiths B et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007; 56:4113–4119.
281. Karlson E, Daltroy L, Rivest C. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003; 12:280–286.
282. Ward M, Marx A, Barry N. The rating scale preference measure as an evaluative measure in systemic lupus erythematosus. Lupus 2000; 9:696–701.
283. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005; 19:685–708.
284. Gladman D, Urowitz M. The SLICC/ACR damage index: progress report and experience in the field. Lupus 1999; 8:632–637.
285. Castrejón I, Rúa-Figueroa I, Rosario M, Carmona L. Índices compuestos para evaluar la actividad de la enfermedad y el daño estructural en pacientes con lupus eritematoso: revisión sistemática de la literatura. Reumatol Clínica 2014; 10:309–320.
286. Gladman D, Ginzler E. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus. Arthritis Rheum 1996; 39:363–369.
287. Rahman P, Gladman D, Urowitz M, Hallett D, Tam L. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10:93–97.
288. Nived O, Jönsen A, Bengtsson A a, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29:1398–1400.
289. Gladman D, Urowitz M, Goldsmith C, Fortin P, Ginzler E, Gordon C et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus. Arthritis Rheum 1997; 40:809–813.
290. Chehab G, Sander O, Richter J, Acar H, Vordenba S. Validation and evaluation of the German Brief Index of Lupus Damage (BILD) – a self-reported instrument to record damage in systemic lupus erythematosus. Lupus 2013; 22:1050–1055.
291. Costenbader KH, Khamashta M, Ruiz-García S, Pérez-Rodríguez MT, Petri M, Elliott J et al. Development and initial validation of a self-assessed lupus organ damage instrument. Arthritis Care Res (Hoboken) 2010; 62:559–568.
292. Yazdany J, Trupin L, Gansky S a, Dall’era M, Yelin EH, Criswell L a et al. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63:1170–1177.
293. Zonana-Nacach A, Salas M, Sánchez M, Camargo-Coronel A, Bravo-Gatica C, Mintz G. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study. J Rheumatol 1995; 22:45–49.
294. Petri M, Singh S, Tesfasyone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009; 36:2476–2480.
295. Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra S V, Cervera R et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013; 65:2143–2153.
296. Navarra S V, Guzmán RM, Gallacher AE, Hall S, Levy R a, Jiménez RE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721–731.
297. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:3918–3930.
298. Alarcón GS, Calvo-Alén J, McGwin G, Uribe a G, Toloza SM a, Roseman JM et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 2006; 65:1168–1174.
299. Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010; 19:1272–1280.
300. Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009; 68:234–237.
301. Tian S, Li J, Wang L, Liu T, Liu H, Cheng G et al. Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm Res 2007; 56:304–310.
302. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11:R143.
303. Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology 2010; 49:960–971.
304. Singh RG, Usha, Rathore SS, Behura SK, Singh NK. Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus 2012; 21:1214–1218.
305. Chan RW-Y, Lai FM-M, Li EK-M, Tam L-S, Chow K-M, Li PK-T et al. Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flare. Rheumatology 2007; 46:44–8.
306. Bauer J, Petri M, Batliwalla F. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum 2009; 60:3098–3107.
307. Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 2014; 66:608–616.
308. Ruiz-Irastorza G, Egurbide M-V, Martínez-Berriotxoa A, Ugalde J, Aguirre C. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 2004; 13:900–905.
309. Mak A, Cheung MW-L, Chiew HJ, Liu Y, Ho RC. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012; 41:830–839.
310. Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 2013; 43:352–361.
311. Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, Pastor-Asurza C a, Alfaro-Lozano JL, Cucho-Venegas JM et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis 2014. doi:10.1136/annrheumdis-2013-204620.
312. Petri M, Purvey S, Fang H, Magder L. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012; 64:4021–4028.
313. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 2012; 64:511–518.
314. Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73:958–967.
315. Pego-Reigosa J, Cobo-Ibáñez T, Calvo-Alén J, Loza-Santamaría E, Rahman A, Muñoz-Fernández S et al. Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res (Hoboken) 2013; 65:1775–1185.
316. Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003; 12:3–7.
317. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:620–625.
318. González-López L, Cardona-Muñoz E, Celis A, García-de la Torre I, Orozco-Barocio G, Salazar-Paramo M. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004; 13:105–112.
319. Petri M, Brodsky R a, Jones RJ, Gladstone D, Fillius M, Magder LS. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum 2010; 62:1487–1493.
320. Hahn B, Kantor O, Osterland K. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med 1975; 83:597–605.
321. Griffiths B, Emery P, Ryan V, Isenberg D, Akil M, Thompson R et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology 2010; 49:723–732.
322. Carneiro J, Sato E. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26:1275–1279.
323. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008; 59:1796–1804.
324. Tam L, Li E, Wong C, Lam C, Szeto C. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004; 13:601–604.
325. Dammacco F, Alberighi O, Ferraccioli G, Racanelli V, Casatta L, Bartoli E. Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Exp Med 2000; 30:67–73.
326. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 2012; 8:522–33.
327. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta M a. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20–8.
328. Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramírez L a, Scherbarth HR et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010; 62:855–862.
329. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61:29–36.
330. Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62:863–868.
331. Sabio J, Zamora-Pasadas M, Jiménez-Jáimez J, Albadalejo F, Vargas-Hitos J, Rodríguez del Águila M. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008; 17:849–859.
332. Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae S-C et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2014;:1–7.
333. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martínez-Berriotxoa A, Egurbide M-V, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009; 11:R109.
334. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011; 147:1261–1267.
335. Cavazzana I, Franceschini F, Belfiore N, Quinzanini M, Caporali R, Calzavara-Pinton P et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheymatology 2001; 17:403–409.
336. Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan T. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9:92–95.
337. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62:775–784.
338. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118:415–422.
339. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 2012; 51:1145–1153.
340. Buttgereit F, Burmester G-R, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005; 365:801–803.
341. Buttgereit F, Straub RH, Wehling M, Burmester G-R. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50:3408–3417.
342. Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011; 20:1484–1493.
343. Yee C-S, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2003; 63:525–529.
344. Fischer-Betz R, Chehab G, Sander O, Vordenbäumen S, Voiculescu A, Brinks R et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol 2012; 39:2111–7.
345. Ruiz-Irastorza G, Danza A, Perales I, Villar I, García M, Delgado S et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev 2014; 13:206–214.
346. Illei GG, Iii HAA, Crane M, Collins L, Gourley MF, Rn CHY. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135:248–257.
347. Mackworth-Young C, David J, Morgan S, Hughes G. A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus. Ann Rheum Dis 1988; 47:496–502.
348. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003; 32:370–377.
349. Zonana-nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43:1801–1808.
350. Thamer M, Hernán M, Zhang Y, Cotter D, Petri M. Relationship between prednisone, lupus activity and permanet organ damage. J Rheumatol 2013; 36:560–564.
351. Ruiz-Arruza I, Ugarte A, Cabezas-Rodríguez I, Medina J-A, Morán M-A, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology 2014; 53:1470–6.
352. Badsha H, Kong K, Lian T, Chan S, Edward C, Chng H. Low-dose pulse methylprednisolone for systemic lupus erythematosus ares is ef cacious and has a decreased risk of infectious complications. Lupus 2002; 11:508–513.
353. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra S V et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71:1833–1838.
354. Van Vollenhoven RF, Petri M a, Cervera R, Roth D a, Ji BN, Kleoudis CS et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71:1343–1349.
355. Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013; 22:144–154.
356. Ramos-Casals M, Ruiz-Irastorza G, Jiménez-Alonso J, Khamashta M a. Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI. Rev clínica espanõla 2013; 213:42–58.
357. Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, Marqués AO, Rúa-Figueroa I, Fernández-Nebro A et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. Semin Arthritis Rheum 2014; 44:175–185.
358. Chen H, Zheng W, Su J, Xu D, Wang Q, Leng X et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study. Rheumatology 2011; 50:1640–1644.
359. Galarza-Maldonado C, Kourilovitch MR, Molineros JE, Cardiel MH, Zurita L, Soroka NF et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. Autoimmun Rev 2010; 10:108–111.
360. Fernández-Nebro A, Marenco JL, Fuente D, Carren L, Olive A. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus 2012; 21:1063–1076.
361. Ramos-Casals M, García-Hernández F, de Ramón E, Callejas J, Martínez-Berriotxoa A, Pallarés L. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28:468–476.
362. García-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltrán-Castillo A, Jiménez-Hernández M et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010; 19:213–219.
363. Hofmann SC, Leandro MJ, Morris SD, Isenberg D a. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature. Lupus 2013; 22:932–939.
364. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222–233.
365. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215–1226.
366. Coca A, Sanz I. B cell depletion in lupus and Sjögren’s syndrome: an update. Curr Opin Rheumatol 2009; 21:483–488.
367. Weidenbusch M, Römmele C, Schröttle A, Anders H-J. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28:106–111.
368. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology 2009; 48:1451–1454.
369. Cortés-Hernández J, Egri N, Vilardell-Tarrés M, Ordi-Ros J. Etanercept in refractory lupus arthritis: An observational study. Semin Arthritis Rheum 2015.
370. Furie R, Nicholls K, Cheng T-T, Houssiau F, Burgos-Vargas R, Chen S-L et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014; 66:379–389.
371. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; 64:3660–3665.
372. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K et al. Tocilizumab in systemic lupus erythematosus - safety, preliminary efficacy, and impact on circulating plasma cells. Arthritis Rheum 2011; 62:542–552.
373. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168–186.
374. Boletis JN, Ioannidis JPA, Boki KA. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis Therapeutic implications of the sentinel lymph node in breast cancer. Lancet 1999; 354:569–570.
375. Monova D, Belovezhdov N, Altunkova I, Monov S. Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. Nephron 2002; 90:262–266.
376. Sherer Y, Kuechler S, Scali JJ, Rovensky J, Levy Y, Zandman-goddard G et al. Low Dose Intravenous Immunoglobulin in Systemic Lupus Erythematosus: Analysis of 62 Cases Isr Med Assoc J 2008; 10:55–57.
377. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F et al. A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus 1999; 8:705–712.
378. Camara I, Sciascia S, Simoes J, Pazzola G, Salas V, Karim Y et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Clin Exp Rheumatol 2014; 32:41–47.
379. Arnal C, Piette J, Léone J, Taillan B, Hachulla E, Roudot-thoraval F et al. Treatment of Severe Immune Thrombocytopenia Associated with Systemic Lupus Erythematosus:59 Cases. J Rheumatol 2002; 29:75–83.
380. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Marcolongo M. Long term I.V. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12:163–168.
381. Tufan F, Kamali S, Erer B, Gul A, Inanc M, Ocal L et al. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin Rheumatol 2007; 26:1913–1915.
382. Van der Goes MC, Jacobs JWG, Boers M, Andrews T, Blom-Bakkers M a M, Buttgereit F et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69:1913– 1919.
383. Schmajuk G, Yazdany J. Drug monitoring in systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 2011; 40:559–575.
384. Boumpas D, Austin H, Vaughn E, Klippel J, Steinberg A, Yarboro C et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741–745.
385. Mitwalli AH, Al Wakeel JS, Hurraib S, Aisha A, Al Suwaida A, Alam A et al. Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial. Saudi J Kidney Dis Transpl 2011; 22:935–940.
386. Sabry A, Abo-Zenah H, Medhat T, Sheashaa H, Mahmoud K, El-Huseini A. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience. Int Urol Nephrol 2009; 41:153–161.
387. Deng J, Huo D, Wu Q, Yang Z, Liao Y. A Meta-Analysis of Randomized Controlled Trials Comparing Tacrolimus with Intravenous Cyclophosphamide in the Induction Treatment for Lupus Nephritis. Tohoku J Exp Med 2012; 227:281–288.
388. Henderson L, Masson P, Craig J, Roberts M, Flanc R, Strippoli G et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61:74–87.
389. Chan T-M, Tse K-C, Tang CS-O, Mok M-Y, Li F-K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16:1076–1084.
390. Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16:707–712.
391. Isenberg D, Appel GB, Contreras G, Dooley M a, Ginzler EM, Jayne D et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010; 49:128–40.
392. Zavada J, Pesickova S, Rysava R, Olejarova M, Horák P, Hrncír Z et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 2010; 19:1281–1289.
393. Austin HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20:901–911.
394. Arends S, Grootscholten C, Derksen RHWM, Berger SP, de Sévaux RGL, Voskuyl AE et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 2012; 71:966–973.
395. Carette S, Klippel J, Decker J, Austin H, Plotz P, Steinberg A et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 1983; 99:1–8.
396. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD et al. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 1982; :728–736.
397. Chen W, Liu Q, Tang X, Fu P, Liu F, Liao Y et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012; 21:944–952.
398. Naughton MA, Battaglia E, Brien SO, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999; 38:640–644.
399. Yap DYH, Yu X, Chen X-M, Lu F, Chen N, Li X-W et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology 2012; 17:352–357.
400. Doria A, Piccoli A, Vesco P, Vaccaro E, Marson P, De Silvestro G et al. Therapy of lupus nephritis. A two-year prospective study. Ann Med Interne (Paris) 1993; 145:307–311.
401. Lewis E, Hunsicker L, Lan S, Rohde R, Lachin J. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326:1373–1379.
402. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger a L, Schroeder JO et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher 1998; 13:163–166.
403. Wei N, Klippel J, Huston D, Hall R, Lawley T, Balow J et al. Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983; 1:17–21.
404. Gaubitz M, Seidel M, Kummer S, Schotte H, Perniok a, Domschke W et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998; 11:495–501.
405. Hershko AY, Scheiman-Elazari A, Aamar S, Naparstek Y. Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study. Immunol Res 2013; 56:376–381.
406. Schiel R, Bambauer R, Latza R, Klinkmann J. Cyclosporine and therapeutic plasma exchange in treatment of progressive autoimmune diseases. Artif Organs 1997; 21:983–988.
407. Soerensen H, Schneidewind-Mueller J-M, Lange D, Kashiwagi N, Franz M, Yokoyama T et al. Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol Int 2006; 26:409–415.
408. Soltész P, Aleksza M, Antal-Szalmás P, Lakos G, Szegedi G, Kiss E. Plasmapheresis Modulates TH1/TH2 Imbalance in Patients with Systemic Lupus Erythematosus According to Measurement of Intracytoplasmic Cytokines. Autoimmunity 2002; 35:51–56.
409. Bambauer R, Schwarze U, Schiel R. Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus. Artif Organs 2000; 24:852–856.
410. Sugimoto K, Yamaji K, Yang K-S, Kanai Y, Tsuda H, Hashimoto H. Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial 2006; 10:187–192.
411. Euler H, Guillevin L. Plasmapheresis and subsequent pulse cyckiphosphamide in severe systemic lupus erythematosus. Ann Médecine Interne 1994; 145:296–302.
412. Danieli M, Plamieri C, Salvi A, Refe M, Strusi A, Danieli G. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher 2002; 17:72–77.
413. Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998; 41:414–420.
414. Pohl M, Lan S, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. Ann Intern Med 1991; 114:924–929.
415. Meinão I, Sato E, Andrade L, Ferraz M, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996; 5:237–241.
416. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324:150–154.
417. Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Hammoud HA, Aymard G, Cacoub P et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:3284–3290.
418. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345:1595–1599.
419. Tseng C-E, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:3623–3632.
420. Sakthiswary R, Raymond AA. The clinical significance of vitamin D in systemic lupus erythematosus: a systematic review. PLoS One 2013; 8:e55275.
421. Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide M-V, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. Arthritis Care Res (Hoboken) 2010; 62:1160–1165.
422. Kuhn A, Sigges J, Biazar C, Ruland V, Patsinakidis N, Landmann A et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol 2014; 171:571–579.
423. Ghaussy NO, Sibbitt W, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003; 30:1215–1221.
424. Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Miettinen A, Julkunen H. Smoking, disease activity, permanent damage and dsDNA autoantibody production in patients with systemic lupus erythematosus. Rheumatol Int 2014; 34:341–345.
425. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42:983–987.
426. Zonana-Nacach A, Roseman JM, Jr GM, Friedman AW, Baethge BA, Reveille JD et al. Systemic lupus erythematosus in three ethnic groups . VI:Factors associated with fatigue within 5 years of criteria diagnosis. Lupus 2000; 9:101–109.
427. Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis 1999; 58:379–381.
428. Hann DM, Jacobsen PB, Azzarello LM, Martin SC, Curran SL, Fields KK et al. Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory. Qual Life Res 1998; 7:301–310.
429. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D et al. Development of a fatigue scale. J Psychosom Res 1993; 37:147–53.
430. Omdal R, Sjöholm H, Koldingsnes W, Sundsfjord J a, Jacobsen E a, Husby G et al. Fatigue in patients with lupus is not associated with disturbances in cerebral blood flow as detected by SPECT. J Neurol 2005; 252:78–83.
431. Taylor J, Skan J, Erb N, Carruthers D, Bowman S, Gordon C et al. Lupus patients with fatigue-is there a link with fibromyalgia syndrome? Rheumatology 2000; 39:620–623.
432. Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63:261–268.
433. Katz P, Yazdany J, Julian L, Trupin L, Margaretten M, Yelin E et al. Impact of obesity on functioning among women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63:1357–1364.
434. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9:170–175.
435. Ahn GE, Ramsey-Goldman R. Fatigue in systemic lupus erythematosus. Int J Clin Rheumtol 2012; 7:217–227.
436. Ad Hoc Committee On Systemic Lupus Erythematosus Response Criteria For Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum 2007; 57:1348–1357.
437. Goligher EC, Pouchot J, Brant R, Kherani RB, Antonio J, Lacaille D et al. Minimal Clinically Important Difference for 7 Measures of Fatigue in Patients with Systemic Lupus Erythematosus. J Rheumatol 2008; 35:635–642.
438. Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs 2006; 56:617–635.
439. Balsamo S, Santos-Neto L Dos. Fatigue in systemic lupus erythematosus: an association with reduced physical fitness. Autoimmun Rev 2011; 10:514–518.
440. Cleanthous S, Tyagi M, Isenberg D a, Newman SP. What do we know about self-reported fatigue in systemic lupus erythematosus? Lupus 2012; 21:465–476.
441. Strömbeck B, Jacobsson L. The role of exercise in the rehabilitation of patients with systemic lupus erythematosus and patients with primary Sjogren’s syndrome. Curr Opin Rheumatol 2007; 19:197–203.
442. De Carvalho MRP, Sato EI, Tebexreni AS, Heidecher RTC, Schenkman S, Neto TLB. Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 53:838–844.
443. Zhang J, Wei W, Wang CM. Effects of psychological interventions for patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus 2012; 21:1077–1087.
444. Greco CM, Kao a H, Maksimowicz-McKinnon K, Glick RM, Houze M, Sereika SM et al. Acupuncture for systemic lupus erythematosus: a pilot RCT feasibility and safety study. Lupus 2008; 17:1108–1116.
445. Hartkamp a, Geenen R, Godaert GLR, Bijl M, Bijlsma JWJ, Derksen RHWM. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann Rheum Dis 2010; 69:1144–1147.
446. Petri M, Mease P, Merrill J, Lahita R, Iannini M, Yocum D et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004; 50:2858–2868.
447. Stockton KA, Kandiah DS, Paratz JD, Bennell KL. Fatigue, muscle strength and vitamin D status in women with systemic lupus erythematosus compared with healthy controls. Lupus 2012; 21:271–278.
448. Ruiz-Irastorza G, Egurbide M V, Olivares N, Martínez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 2008; 47:920–923.
449. Tench C, Bentley D, Vleck V, Mccurdie IAN, White P, Cruz DD. Aerobic Fitness , Fatigue , and Physical Disability in Systemic Lupus Erythematosus. J Rheumatol 2002; 29:474–481.
450. Bourré-Tessier J, Peschken C a, Bernatsky S, Joseph L, Clarke AE, Fortin PR et al. Association of smoking with cutaneous manifestations in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013; 65:1275–1280.
451. Turchin I, Bernatsky S, Clarke AE, St-Pierre Y, Pineau C a. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J Rheumatol 2009; 36:2691–2693.
452. Barta Z, Harrison MJ, Wangrangsimakul T, Shelmerdine J, Teh L, Pattrick M et al. Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. Lupus 2010; 19:231–238.
453. Yuen HK, Breland HL, Vogtle LK, Holthaus K, Kamen DL, Sword D. The process associated with motivation of a home-based Wii Fit exercise program among sedentary African American women with systemic lupus erythematosus. Disabil Health J 2013; 6:63–68.
454. Robb-Nicholson L, Daltroy L, Eaton H, Gall V, Wrightt E, Hartley L et al. Effects of aerobic conditioning in lupus fatigue: A pilot study. Brithish J Rheumatol 1989; 28:500– 505.
455. Miossi R, Benatti FB, Lúciade de Sá Pinto A, Lima FR, Borba EF, Prado DML et al. Using exercise training to counterbalance chronotropic incompetence and delayed heart rate recovery in systemic lupus erythematosus:a randomized trial. Arthritis Care Res (Hoboken) 2012; 64:1159–1166.
456. Ramsey-Goldman R, Schilling EM, Dunlop D, Langman C, Greenland P, Thomas RJ et al. A pilot study on the effects of exercise in patients with systemic lupus erythematosus. Arthritis Care Res 2000; 13:262–269.
457. Yuen HK, Holthaus K, Kamen DL, Sword DO, Breland HL. Using Wii Fit to reduce fatigue among African American women with systemic lupus erythematosus: A pilot study. Lupus 2011; 20:1293–1299.
458. Tench CM, McCarthy J, McCurdie I, White PD, D’Cruz DP. Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology 2003; 42:1050– 1054.
459. Clarke-Jenssen A-C, Fredriksen PM, Lilleby V, Mengshoel AM. Effects of supervised aerobic exercise in patients with systemic lupus erythematosus: a pilot study. Arthritis Rheum 2005; 53:308–312.
460. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, Ragavendra N et al. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62:258–265.
461. Barnes JN, Nualnim N, Sugawara J, Sommerlad SM, Renzi CP, Tanaka H. Arterial stiffening, wave reflection, and inflammation in habitually exercising systemic lupus erythematosus patients. Am J Hypertens 2011; 24:1194–1200.
462. Shah M, Adams-huet B, Kavanaugh A, Coyle Y, Lipsky P. Nutrient Intake and Diet Quality in Patients with Systemic Lupus Erythematosus on a Culturally Sensitive Cholesterol Lowering Dietary Program. J Rheumatol 2004; 31:71–75.
463. Shah M, Kavanaugh A, Coyle Y, Adams-huet B, Lipsky PE. Effect of a Culturally Sensitive Cholesterol Lowering Diet Program on Lipid and Lipoproteins, Body Weight , Nutrient Intakes, and Quality of Life in Patients with Systemic Lupus Erythematosus. J Rheumatol 2002; 29:2122–2128.
464. Davies RJ, Lomer MCE, Yeo SI, Avloniti K, Sangle SR, Cruz DPD. Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids. Lupus 2012; 21:649–655.
465. Wright SA, O’Prey FM, McHenry MT, Leahey WJ, Devine a B, Duffy EM et al. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008; 67:841–848.
466. Walton AJE, Snaith ML, Locniskar M, Cumberland AG, Morrow WJW, Isenberg DA. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 1991; 50:463–466.
467. Duffy E, Meenagh G, McMillan S, Strain J, Hannigan B, Bell A. The clinical effect of dietary supplementation with omega-3 fish oil and/or copper in systemic lupus erythematosus. J Rheumatol 2004; 31:1551–1556.
468. Elkan A, Anania C, Gustafsson T, Jogestrand T, Hafstro I, Frostega J. Diet and fatty acid pattern among patients with SLE: associations with disease activity , blood lipids and atherosclerosis. Lupus 2012; 21:1405–1411.
469. Minami Y, Sasaki T, Arai Y, Kurisu Y, Hisamichi S. Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. J Rheumatol 2003; 30:747–754.
470. Kaimal S, Abraham A. Sunscreens. Indian J Dermatology, Venereol Leprol 2011; 77:238– 243.
471. Marenus K, Maes D. Infrared: effects and protection. Cosmet Dermatology 1994; 6:197– 205.
472. Herzinger T, Plewig G, Röcken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004; 50:3045–3046.
473. Millard T, Hawk J, McGregor J. Photosensitivity in lupus. Lupus; 9:3–10.
474. Sambandan DR, Ratner D. Sunscreens: an overview and update. J Am Acad Dermatol 2011; 64:748–758.
475. Gilaberte Y, Coscojuelaa C, Sáenz de Santamaría M, González S. Fotoprotección. Actas Dermosifiliogr 2003; 94:271–293.
476. Sanders CJG, Weelden HVAN, Kazzaz GAA, Sigurdsson V. Photobiology Photosensitivity in patients with lupus erythematosus: a clinical and photobiologica study of 100 patients using a prolonged phototest protocol. Br J Dermatol 2003; 149:131–137.
477. Kuhn a, Sonntag M, Richter-Hintz D, Oslislo C, Megahed M, Ruzicka T et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001; 45:86–95.
478. Rihner M, McGrath Hj. Fluorescent Light Photosensitivity in patients with systemic lupus erythematosus. Arthritis Rheumatol 1992; 35:949–952.
479. Lehmann P, Hölzle E, Kind P, Goerz G, Plewig G. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990; 22:181–187.
480. Vilá L, Mayor A, Valentín A, Rodríguez S, Reyes M, Acosta E et al. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. P R Health Sci J 1999; 18:89–94.
481. Kuhn A, Gensch K, Haust M, Meuth A-M, Boyer F, Dupuy P et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol 2011; 64:37–48.
482. Stege H, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol Photoimmunol Photomed 2000; 16:256–259.
483. Sigges J, Biazar C, Landmann A, Ruland V, Patsinakidis N, Amler S et al. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 2013; 12:694–702.
484. Cano L, Navas-Fernández R, López-Lasanta M, Jiménez-Núñez F, Ureña I, Manrique S et al. Efectos sobre la calidad de vida de un programa educacional enfocado para pacientes con lupus eritematoso sistémico. 2011.
485. Karlson EW, Liang MH, Eaton H, Huang J, Fitzgerald L, Rogers MP et al. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum 2004; 50:1832–1841.
486. Austin JS, Maisiak RS, Macrina DM, Heck LW. Health Outcome Improvements in Patients with Systemic Lupus Erythematosus Using Two Telephone Counseling Interventions. Arthritis Care Res 1996; 9:391–399.
487. Maisiak R, Austin J, West S, Heck L. The effect of person-centered counseling on the psychological status of persons with systemic lupus erythematosus or rheumatoid arthritis. A randomized, controlled. Arthritis Rheum 1996; 9:60–66.
488. Sohng KY. Effects of a self-management course for patients with systemic lupus erythematosus. Issues Innov Nurisng Pract 2003; 42:479–486.
489. Harrison MJ, Morris KA, Horton R, Toglia J, Barsky J, Chait S et al. Results of intervention for lupus patients with self- perceived cognitive difficulties. Neurology 2005; 65:1325–1327.
490. Braden C, McGlone K, Pennington F. Specific psychosocial and behavioral outcomes from the systemic lupus erythematosus self-help course. Health Educ Q 1993; 20:29–41.
491. Haupt M, Millen S, Jänner M, Falagan D, Fischer-Betz R, Schneider M. Improvement of coping abilities in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 2005; 64:1618–1623.
492. Cervera R, Khamashta M a, Font J, Sebastiani GD, Gil A, Lavilla P et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period:a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299–308.
493. Weening JJ. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. J Am Soc Nephrol 2004; 15:241–250.
494. Seshan S V, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med 2009; 133:233–248.
495. Giannico G, Fogo AB. Lupus nephritis:is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol 2013; 8:138–145.
496. Hahn BH, McMahon M a, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64:797–808.
497. González-Crespo MR, López-Fernández JI, Usera G, Poveda MJ, Gómez-Reino JJ. Outcome of silent lupus nephritis. Semin Arthritis Rheum 1996; 26:468–476.
498. Christopher-Stine L, Sieder M, Lin J, Haas M, Parekh H, Petri M et al. Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 2007; 34:399–400.
499. Wu L-H, Yu F, Tan Y, Qu Z, Chen M-H, Wang S-X et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013; 83:715–723.
500. Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 2007; 71:491–495.
501. Hiramatsu N, Kuroiwa T, Ikeuchi H, Maeshima A, Kaneko Y, Hiromura K et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology 2008; 47:702–707.
502. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18:244–254.
503. Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol Dial Transplant 2008; 23:223–230.
504. Kojo S, Sada K, Kobayashi M, Maruyama M, Maeshima Y, Sugiyama H et al. Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis. J Rheumatol 2009; 36:2218–2223.
505. Gao J, Cai G, Liu S, Tang L, Zhang X, Yang Y et al. Characteristics and influence factors of pathologic transformation in the subclasses of class IV lupus nephritis. Rheumatol Int 2012; 32:1751–1759.
506. Hill GS, Delahousse M, Nochy D, Bariéty J. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005; 68:2288–2297.
507. Austin H, Muenz R, Joyce K, Antonovych T, Balow J. Diffuse prolifertative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25:689–695.
508. Daleboudt GMN, Bajema IM, Goemaere NNT, van Laar JM, Bruijn J a, Berger SP. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 2009; 24:3712–3727.
509. Anders H-J, Weening JJ. Kidney disease in lupus is not always ‘lupus nephritis’. Arthritis Res Ther 2013; 15:108.
510. Moroni G, Pasquali S, Quaglini S. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34:530–539.
511. Gunnarsson I, Sundelin B, Heimbürger M, Forslid J, Vollenhoven R Van, Lundberg I et al. Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q Repeated Renal Biopsy in Proliferative Lupus Nephritis — Predictive Role of Serum C1q and Albuminuria. J Rheumatol 2002; 29:693–699.
512. Alsuwaida A, Husain S, Alghonaim M, AlOudah N, Alwakeel J, Ullah A et al. Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant 2012; 27:1472–1478.
513. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens 2005; 14:1–8.
514. Frutos MÁ, Praga M, Quereda C, Rivera F, Segarra A. Lupus nephritis:in search of a better future. Nefrologia 2012; 32:136–138.
515. Kanda H, Kubo K, Tateishi S, Sato K, Yonezumi A, Yamamoto K et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005; 14:288–292.
516. De Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP et al. An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int 2004; 65:846–859.
517. MacKinnon M, Shurraw S, Akbari A, Knoll G a, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48:8–20.
518. Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ. The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther 2008; 10:R5.
519. Teplitsky V, Shoenfeld Y, Tanay A. The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus 2006; 15:319–325.
520. Durán-Barragán S, McGwin G, Vilá LM, Reveille JD, Alarcón GS. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-- results from LUMINA (LIX): a multiethnic US cohort. Rheumatology 2008; 47:1093– 1096.
521. Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Aymard G, Leroux G, Marra D et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007; 66:821– 824.
522. Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus 2013; 22:1135–1141.
523. Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J. Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010; 25:3939–3948.
524. Fei Y, Wu Q, Zhang W, Chen H, Hou Y, Xu D et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol 2013; 31:62–68.
525. Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012; 11:357–364.
526. Renal disease subcomite of the American collegue of rheumatology ad hoc comite on systemic lupus erythematosus response criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54:421–432.
527. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18:257–263.
528. Touma Z, Urowitz M, Ibáñez D, Gladman D, Ibáñez D. Time to Recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol 2014; 41:688–697.
529. Donadio J, Holley K, Ferguson R, Ilstrup D. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. New Engl J ... 1978; 299:1151–1155.
530. Felson D, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984; 311:1528–1533.
531. Balow J, Austin H, Muenz L, Joyce K, Antonovych T, Klippel J et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984; 3:491–495.
532. Austin H, Klippel J, Balow J, Le Riche N, Steinberg A, Plotz P et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614–619.
533. Steinberg A, Steinberg S. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheumatol 1991; 34:945–950.
534. Gourley M, Austin H, Scott D, Yarboro C, Vaugham E, Muir J et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125:549–557.
535. Sesso R, Monteiro M, Sato E, Kirsztaijn G, Silva L, Ajzen H. A controlled trial of pulse cyclophospgamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994; 3:107–112.
536. Bansal VK, Beto J a. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997; 29:193–199.
537. Flanc RS, Roberts M a, Strippoli GF., Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43:197–208.
538. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani, Gian Domenico Garrido E de R, Danieli MG, Abramovicz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121–2131.
539. Kong K, Badsha H, Lian T, Edwards C, Chng H. Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus 2004; 13:525–529.
540. Boumpas D, Austin H, Vaughan E, Yarboro C, Klippel J, Balow J. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366–369.
541. Ioannidis J, Katsifis G, Tzioufas A, Moutsopoulos H. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002; 29:2129–2135.
542. Mok C, Lau C, Wong R. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheumatol 1998; 41:831–837.
543. Park M, Park Y, Jung S, Chung I, Choi K, Lee S. Risk of ovarian failure and pregnancy outcome in patients treated with intravenous cyclophosphamide pulse therapy. Lupus 2014; 13:569–574.
544. Appenzeller S, Blatyta PF, Costallat LTL. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol Int 2008; 28:567–571.
545. Martín-Gómez M, De Ramón-Garrido E, Frutos M. Pasado y presente del tratamiento Inmunosupresor de la de la Nefritis Lúpica en la provincia de Málaga. 2011.
546. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103–1112.
547. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O´Nan P et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971–980.
548. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69:61–64.
549. Lee YH, Lee HS, Choi SJ, Dai Ji J, Song GG. Efficacy and safety of tacrolimus therapy for lupus nephritis:a systematic review of clinical trials. Lupus 2011; 20:636–640.
550. Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005; 100:c92–c100.
551. Ginzler E, Dooley M, Aranow C, Kim M, Buyon J, Merrill JT et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353:2219–2228.
552. Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore) 2010; 89:227–235.
553. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10:504–510.
554. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol 2011; 38:69–78.
555. Neumann I, Fuhrmann H, Fang I-F, Jaeger A, Bayer P, Kovarik J. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008; 23:3514–3520.
556. Liu L, Jiang Y, Wang L, Yao L, Li Z. Efficacy and Safety of Mycophenolate Mofetil versus Cyclophosphamide for Induction Therapy of Lupus Nephritis. Drugs 2012; 72:1521–1533.
557. Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S, Avihingsanon Y. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 2010; 78:389–395.
558. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake a WL, de Glas-Vos JW, Bijl M et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70:732–742.
559. Wang S, Li X, Qu L, Wang R, Chen Y, Li Q et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus 2012; 21:1025–1035.
560. Yang M, Li M, He W, Wang B, Gu Y. Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis. Exp Ther Med 2014; 7:1663–1670.
561. Moroni G, Gallelli B, Sinico RA, Romano G, Sinigaglia L, Messa P. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann Rheum Dis 2012; 71:1751–2.
562. Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014; 54. doi:10.1093/rheumatology/ket462.
563. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta M a. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009; 18:767–776.
564. Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72:1280–1286.
565. Mohan S, Radhakrishnan J. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol 2011; 75:233–241.
566. Wilson ECF, Jayne DRW, Dellow E, Fordham RJ. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology (Oxford) 2007; 46:1096–1101.
567. Kellum J a, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17:204.
568. Zhu D, Qu Z, Tan Y, Yu F, Zhao M-H. Acute kidney injury in Chinese patients with lupus nephritis: a large cohort study from a single center. Lupus 2011; 20:1557–1565.
569. Ponte B, Felipe C, Muriel A, Tenorio MT, Liaño F. Long-term functional evolution after an acute kidney injury: a 10-year study. Nephrol Dial Transplant 2008; 23:3859–3866.
570. Chen T, Ding X, Chen B. Value of the RIFLE classification for acute kidney injury in diffuse proliferative lupus nephritis. Nephrol Dial Transplant 2009; 24:3115–3120.
571. Yu F, Tan Y, Liu G, Wang S, Zou W, Zhao M. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009; 76:307–317.
572. Chin HJ, Ahn C, Lim CS, Chung HK, Lee JG, Song YW et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol 2000; 20:57–63.
573. Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH. Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus 2010; 19:1591–8.
574. Yu F, Wu L-H, Tan Y, Li L-H, Wang C-L, Wang W-K et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010; 77:820–9.
575. Walsh M, Solomons N, Lisk L, Jayne DRW. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 2013; 61:710–715.
576. Rivera F, Illescas ML, López-Rubio E, Fulladosa J, Poveda R, Baltar J et al. Mycophenolate as maintenance therapy for lupus nephritis with impaired renal function. Am J Nephrol 2013; 37:509–517.
577. Kong KO, Badsha H, Lian TY, Edwards CJ, Chng HH. Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Letter to the Editor. Lupus 2004; 13:212–213.
578. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61:1495–1501.
579. Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69:2083–2089.
580. Stoenoiu MS, Aydin S, Tektonidou M, Ravelingien I, le Guern V, Fiehn C et al. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis:data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012; 27:1924–1930.
581. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886–1895.
582. Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007; 56:924–937.
583. Feng L, Deng J, Huo D-M, Wu Q-Y, Liao Y-H. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology 2013; 18:104–110.
584. Moroni G, Doria A, Mosca M, Alberighi ODC, Ferraccioli G, Todesco S et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1:925–932.
585. Zavada J, Sinikka P, Rysava R, Horak P, Hrneir Z, Lukac J et al. Extended follow-up of the Cyclofa-Lune trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. Lupus 2014; 23:69–74.
586. Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006; 21:1541–1548.
587. Cortés-Hernández J, Ordi-Ros J, Labrador M, Segarra A, Tovar JL, Balada E et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12:287–296.
588. Hui M, Garner R, Rees F, Bavakunji R, Daniel P, Varughese S et al. Lupus nephritis: a 15-year multi-centre experience in the UK. Lupus 2013; 22:328–332.
589. Ponticelli C, Moroni G, Banfi G. Discontinuation of therapy in diffuse proliferative lupus nephritis. Am J Med 1988; 85:275.
590. Moroni G, Banfi G, Ponticelli C. Clinical status of patients after 10 years of lupus nephritis. Q J Med 1992; 305:681–689.
591. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22:2531– 2539.
592. Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002; 61:1502– 1509.
593. Mok CC, Ying KY, Yim CW, Ng WL, Wong WS. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 2009; 18:1091–1095.
594. Moroni G, Longhi S, Giglio E, Messa P, Ponticelli C. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol 2013; 31:S75– S81.
595. Mosca M, Neri R, Giannessi S, Pasquariello A, Puccini R, Bencivelli W et al. Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus 2001; 10:253–257.
596. Martín-Gómez M, De Ramón-Garrido E, Frutos M. Pasado y presente de la terapia inmunosupresora de la nefritis lúpica. 2011.
597. Chan TM, Tse KC, Tang CSO, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14:265–272.
598. Euler H, Schroeder J. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 12:1784–1794.
599. Sharon E, Kaplan D, Diamond H. Exacerbation of systemic lupus erythematosus after withdrawal of azahioprine therapy. N Engl J Med 2010; 288:121–124.
600. Mok C, Ho C, Chan K, Lau C, Wong R. Outcome and Prognostic Indicators of Diffuse Proliferative Lupus Glomerulonephritis Treated With Sequential Oral Cyclophosphamide and Azathioprine. Arthritis ... 2002; 46:1003–1013.
601. Ioannidis JP, Boki K a, Katsorida ME, Drosos a a, Skopouli FN, Boletis JN et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57:258–264.
602. Mercadal L, Montcel ST Du, Nochy D, Queffeulou G, Piette J-C, Isnard-Bagnis C et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17:1771–1778.
603. Desai N, Cimbaluk D, Lewis EJ, Whittier WL. Proteinuria in membranous lupus nephritis: the pathology is in the podocyte. Lupus 2013; 22:461–468.
604. Rezende GM, Viana VS, Malheiros DM a C, Borba EF, Silva N a S, Silva C et al. Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria? Lupus 2014; 23:255–262.
605. Moroni G, Quaglini S, Gravellone L, Gallelli B, Leoni A, Messa P et al. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin Arthritis Rheum 2012; 41:642–651.
606. Balow J, Austin H. Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 2003; 23:386–391.
607. Wang G, Xu Z, Liu H, Zhou Q. Changes in pathological pattern and treatment regimens based on repeat renal biopsy in lupus nephritis. Chin Med J (Engl) 2012; 125:2890–2894.
608. Pasquali S, Banfi G, Zucchelli A, Moroni G, Ponticelli C, Zucchelli P. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39:178–182.
609. Sloan RP. Long-term outcome in systemic lupus erythematosus mebranous glomerulonephritis. J Am Soc Nephrol 1996; 7:299–305.
610. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G et al. Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. Ann Intern Med 2001; 135:73–87.
611. Giatras I, Lau J, Levey A. Effect of angiotensin-Converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127:337–345.
612. Swan J, Riche D. Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis. J Investig Med 2011; 59:246–258.
613. Radhakrishnan J, Moutzouris D-A, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77:152–160.
614. Kasitanon N, Petri M, Haas M, Magder LS, Fine DM. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus 2008; 17:40–45.
615. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 2009; 24:15–20.
616. Mok CC, Ying KY, Lau CS, Yim CW, Ng WL, Wong WS et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004; 43:269–276.
617. Stasi R. How to approach thrombocytopenia. Hematology 2012; 2012:191–197.
618. Sanz MÁ, Vicente García V, Fernández A, López MF, Grande C, Jarque I et al. Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia. Med Clin (Barc) 2012; 138:261.e1–261.e17.
619. Boxer LA. How to approach neutropenia. Hematology 2012; 2012:174–182.
620. Newman KA, Akhtari M. Management of autoimmune neutropenia in Felty’s syndrome and systemic lupus erythematosus. Autoimmun Rev 2011; 10:432–437.
621. Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood 2010; 116:1831–1838.
622. Cheng Y, Wong R, Soo Y, Chui C, Lau F, Chan N et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. New Engl J Med 2003; 349:831–836.
623. Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006; 15:223–231.
624. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109:1401–1407.
625. Praituan W, Rojnuckarin P. Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial. J Thromb Haemost 2009; 7:1036–1038.
626. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115:2755–2762.
627. Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol 2013; 90:494–500.
628. Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013; 121:1976–1981.
629. Zhao H, Li S, Yang R. Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis. Platelets 2010; 21:380–385.
630. Ziakas PD, Giannouli S, Zintzaras E, Tzioufas a G, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005; 64:1366–1369.
631. Maroun MC, Ososki R, Andersen J, Vasey FB, Dhar JP. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura (ITP) in systemic lupus erythemathosus (SLE), report of three cases. Arthritis Rheum 2011; 63:746–750.
632. Magnano L, Enríquez H, Esteve J, Cervera R, Espinosa G. Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus The Journal of Rheumatology is a monthly international serial edited by Earl D. J Rheumatol 2014; 41:9–11.
633. Scheinberg P, Singulane CC, Barbosa LSG, Scheinberg M. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. Clin Rheumatol 2014; 33:1347–1349.
634. Alkaabi JK, Alkindi S, Riyami N Al, Zia F, Balla LM a, Balla SM. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus 2012; 21:1571–1574.
635. Maroun M, Ososki R, Andersen J, Vasey F, Dhar J. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura (ITP) in systemic lupus erythemathosus (SLE), report of three cases. 2011.
636. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 2010; 49:2243–2254.
637. González-Nieto JA, Martín-Suárez I, Quattrino S, Ortíz-López E, Muñoz-Beamud FR, Colchero-Fernández J et al. The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus 2011; 20:1321–1323.
638. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641–648.
639. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161–2171.
640. Khellaf M, Le Moine J-G, Poitrinal P, Francesconi C, Haddad A, Bierling P et al. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol 2011; 90:441–446.
641. Kuter D, Rummel M, Boccia R, Macik G, Pabinger I, Selleslag D et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889–1899.
642. Michel M, te Boekhorst PAW, Janssens A, Pabinger-Fasching I, Sanz MA, Nie K et al. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology 2011; 16:274–277.
643. Greenberg BM. The neurologic manifestations of systemic lupus erythematosus. Neurologist 2009; 15:115–21.
644. Yoshio T, Hirata D, Onda K, Nara H, Minota S. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 2005; 32:34–39.
645. Abdel-Nasser AM, Ghaleb RM, Mahmoud JA, Khairy W, Mahmoud RM. Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol 2008; 27:1377–1385.
646. Briani C, Lucchetta M, Ghirardello a, Toffanin E, Zampieri S, Ruggero S et al. Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun 2009; 32:79–84.
647. Jönsen A, Bengtsson A, Nived O, Ryberg B, Truedsson L, Rönnblom L et al. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 2003; 12:846–850.
648. Williams RC, Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004; 50:1239–1247.
649. Kang EH, Shen GQ, Morris R, Metzger A, Lee EY, Lee YJ et al. Flow cytometric assessment of anti-neuronal antibodies in central nervous system involvement of systemic lupus erythematosus and other autoimmune diseases. Lupus 2008; 17:21–25.
650. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 58:1130–1135.
651. Galeazzi M, Annunziata P, Sebastiani G, Bellisai F, Campanella V, Ferrara G et al. Anti ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE. J Rheumatol 2000; 72:135–141.
652. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol 2005; 19:799–821.
653. Abda EA, Selim ZI, Radwan MEM. Markers of acute neuropsychiatric systemic lupus erythematosus: a multidisciplinary evaluation. Rheumatol Intenational 2013; 33:1243– 1253.
654. Sibbitt W, Brooks W, Haseler L, Griffey R, Frank L, Hart B et al. Spin-Spin relaxation of brain tissues in systemic lupus erythematosus: a method for increasing the sensitive of magnetic resonance imaging for neuropsychiatric lupus. Arthritis Rheum 1995; 38:810–818.
655. Waterloo K, Omdal R, Sjöholm H, Koldingsnes, Jacobsen E, Sundsfjord J et al. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J Neurol 2001; 248:595–602.
656. Kodama K, Okada S, Hino T, Takabayashi K, Nawata Y, Uchida Y et al. Single photon emission computed tomography in systemic lupus erythematosus with psychiatric symptoms. J Neurol Neurosurg Psychiatry 1995; 58:307–311.
657. Kozora E, Ellison MC, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51:810–818.
658. Nowicka-Sauer K, Czuszyisska Z Smolesska , Siebert J. Neuropsychological assessmen in systemic lupus erythematosus patients: clinica usefulness of first-choice diagnostic tests in detecting cognitive impairment and preliminary diagnosis of neuropsychiatric lupus. Clin Exp Rheumatol 2011; 29:299–306.
659. Roebuck-Spencer TM, Yarboro C, Nowak M, Takada K, Jacobs G, Lapteva L et al. Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55:434–441.
660. Hanly JG, Omisade A, Su L, Farewell V, Fisk JD. Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests. Arthritis Rheum 2010; 62:1478–1486.
661. Neuwelt CM, Francisco S, Lacks S, Kaye BR, Ellman JB, David GB. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98:32–41.
662. Bodani M, Kopelman M. A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus. Lupus 2003; 12:947–949.
663. Fong KY, Thumboo J. Neuropsychiatric lupus: clinical challenges , brain-reactive autoantibodies and treatment strategies. Lupus 2010; 19:1399–1403.
664. Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 2007; 36:329–337.
665. Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115:59–62.
666. Narváez J, Ríos-Rodríguez V, de la Fuente D, Estrada P, López-Vives L, Gómez-Vaquero C et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 2011; 41:364–372.
667. Prevoo M, van´t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P. Modified disease activity scores thar included twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatic arthritis. Arthritis Rheum 1995; 38:44–48.
668. Bang S-Y, Lee CK, Kang YM, Kim H-A, Suh C-H, Chung WT et al. Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis 2012; 2012:1–6.
669. Fernández D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2983–2988.
670. Islam N, Hossain M, Haq SA, Alam MN, Klooster PMTEN, Rasker JJ. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis 2012; 15:62–68.
671. Moosig FÃ, Zeuner R, Renk C, Schro JO. IL-1RA in refractory systemic lupus erythematosus. Lupus 2004; 13:605–606.
672. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005; 64:630–633.
673. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley M-A. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010; 62:211–221.
674. Albrecht J, Taylor ÃL, Berlin JA, Dulay S, Ang ÃG, Fakharzadeh S et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus. J Invest Dermatol 2005; 125:889–894.
675. Bonilla-Martínez Z, Albrecht J, Troxel A, Taylor L, Okawa J, Dulay S et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2010; 144:173–180.
676. Krathen MS, Dunham J, Gaines E, Junkins-Hopkins J, Kim E, Kolasinski SL et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum 2008; 59:338–344.
677. Salphale P, Danda D, Chandrashekar L, Peter D, Jayaseeli N, George R. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus. Lupus 2011; 20:1510–1517.
678. Klein R, Moghadam-kia S, Lomonico J, Okawa J, Coley C, Taylor L et al. Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus. Arch Dermatol 2011; 147:203–208.
679. Jolly M, Kazmi N, Mikolaitis R a, Sequeira W, Block J a. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol 2013; 68:618–623.
680. Kuhn a, Meuth a M, Bein D, Amler S, Beissert S, Böhm M et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010; 163:83–92.
681. Roenigk HJ, Martin J, Eichorn P, Gilliam J. Discoid lupus erythematosus: diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980; 25:281–285.
682. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008; 64:337–341.
683. Tzung T-Y, Liu Y-S, Chang H-W. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007; 156:191–192.
684. Tlacuilo-Parra A, Guevara-Gutiérrez E, Gutiérrez-Murillo F, Soto-Ortiz A, Barba-Gómez F, Hernández-Torres M et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology 2005; 44:1564–1568.
685. Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stücker M, Bader A et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51:407–410.
686. Lampropoulos C, Sangle S, Harrison P, Hughes G, D’Cruz D. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43:1383–5.
687. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatology 2002; 12:50–52.
688. Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011; 65:54–64.
689. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295–306.
690. Wahl D, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus A metaCanalysis. Lupus 1997; 6:467–473.
691. Bruce IN. ‘Not only...but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44:1492–1502.
692. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20:206–218.
693. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta M a. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20–28.
694. Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014; 13:281–291.
695. Petri M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am 1994; 20:87–118.
696. Derksen R, Bruinse H, de Groot P, Kater L. Pregnancy in systemic lupus erythematosus: a prospective study. Lupus 1994; 3:149–155.
697. Ruiz-Irastorza G, Khamashta M a. Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest 2011; 41:672–678.
698. Smyth A, Oliveira GHM, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5:2060–2068.
699. Le Thi D, Wescgler B, Piette J, Bletry O, Godeau P. Pregnancy and its outcome in systemic lupus erythematosus. QJM An Int J Med 1994; 87:721–729.
700. Clowse MEB, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52:514–521.
701. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Vignati G et al. Risk of Congenital Complete Heart Block in Newborns of Mothers With Anti-Ro / SSA Antibodies Detected by Counterimmunoelectrophoresis A Prospective Study of 100 Women. Arthritis Rheum 2001; 44:1832–1835.
702. Ateka-barrutia O, Nelson-Piercy C. Management of rheumatologic diseases in pregnancy Review. Int J Clin Rheumtol 2012; 7:541–558.
703. Baer AN, Witter FR, Petri M. Lupus and pregnancy. Obstet Gynecol Surv 2011; 66:639– 653.
704. Bramham K, Soh MC, Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus 2012; 21:1271–1283.
705. Carmona F, Font J, Cervera R, Muñoz F, Cararach V, Balasch J. Obstetrical outcome of pregnancy in patients with systemic Lupus erythematosus. A study of 60 cases. Eur J Obstet Gynecol Reprod Biol 1999; 83:137–142.
706. Mintz G, Niz J, Gutiérrez G, García-Alonso A, Karchmer S. Prospective study of pregnancy in sistemic lupus erytematosus. Results of multidisciplinary approach. J Rheumatol 1986; 13:732–739.
707. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Andreu MR et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 2006; 45:332–338.
708. Clowse MEB, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54:3640–3647.
709. Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 2011; 38:2504–2508.
710. Vroom F, de Walle HEK, van de Laar M a JF, Brouwers JRBJ, de Jong-van den Berg LTW. Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf 2006; 29:845–863.
711. Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 2013; 39:58–62.
712. Ruiz-Irastorza G, Khamashta M a. Antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2007; 33:287–297.
713. Petri M, Qazi U. Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2006; 32:591–607.
714. Bouvier S, Cochery-Nouvellon É, Lavigne-Lissalde G, Mercier É, Marchetti T, Balducchi J et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123:404–413.
715. Empson M, Epi MMC, Lassere M, Craig JC, Scott JR. Recurrent Pregnancy Loss With Antiphospholipid Antibody: A Systematic Review of Therapeutic Trials Obstet Gynecol 2002; 99:14–16.
716. Mak A, Cheung MW-L, Cheak AA, Ho RC-M. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 2010; 49:281–288.
717. Ziakas P, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss. Obstet Ginecol 2010; 115:1256–1262.
718. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376:1498–1509.
719. Carmona F, Font J, Azulay M, Creus M, Fábregues F, Cervera R et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001; 46:274–279.
720. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant (Review). Cochrane Libr 2007; 4:1–59.
721. Bramham K, Thomas M, Nelson-piercy C, Khamashta M, Hunt BJ. Brief report First trimester low-dose prednisolone in refractory antiphospholipid antibody–related pregnancy loss. Thromb Hemost 2015; 117:6948–6952.
722. Guballa N, Sammaritano L, Schwartzman S, Buyon J, Lockshin MD. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000; 43:550–556.
723. Huong DLT, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Lefebvre G et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin Arthritis Rheum 2002; 32:174–188.
724. Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis J, Xhakravarty E et al. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality? Arthritis Care Res (Hoboken) 2011; 63:358–365.
725. Culwell K, Curtis K, Cravioto M. Safety of Contraceptive Method Use Among Women With Systemic Lupus Erythematosus A Systematic Review the safety of contraceptive use among women with SLE . Obstet Gynecol 2009; 114:341–353.
726. Sánchez-Guerrero J, Uribe A, Jiménez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc A et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2539–2549.
727. Chabbert-Buffet N, Amoura Z, Scarabin P-Y, Frances C, Lévy DP, Galicier L et al. Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception 2011; 83:229–237.
728. Rubin L, Urowitz M, Gladman D. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985; 55:87–98.
729. Skamra C, Ramsey-goldman R. Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol 2010; 5:75–100.
730. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013; 43:77–95.
731. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44:2331–2337.
732. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of First-Time acute myocardial infarction. Am J Cardiol 2004; 93:198–200.
733. Bengtsson C, Öhman M, Nived O, Rantapa S. Cardiovascular event in systemic lupus erythematosus in northern Sweden: Incidence and predictors in a 7-year follow-up study Lupus 2012; 21:452–459.
734. Hak A, Karlson E, Feskanich D, Stampfer M, Costenbader KH. Systemic lupus erythematosus and risk of cardiovascular disease. Results from the Nurses’ Health Study. Arthritis Rheum 2010; 61:1396–1402.
735. Chiu C-C, Huang C-C, Chan W-L, Chung C-M, Huang P-H, Lin S-J et al. Increased Risk of Ischemic Stroke in Patients with Systemic Lupus Erythematosus: A Nationwide Population-based Study. Intern Med 2012; 51:17–21.
736. Goldberg RJ, Urowitz MB, Ibañez D, Nikpour M, Gladman DD. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009; 36:2454–2461.
737. Haque S, Gordon C, Isenberg D, Rahman A, Lanyon P, Bell A et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol 2010; 37:322–329.
738. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012; 176:708–19.
739. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger T a, Jansen-McWilliams L et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145:408–415.
740. Mok CC, Tang SSK, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52:2774–2782.
741. Pons-Estel GJ, González L a, Zhang J, Burgos PI, Reveille JD, Vilá LM et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology 2009; 48:817–822.
742. Rhew EY, Manzi SM, Dyer AR, Kao AH, Danchenko N, Barinas-mitchell E et al. Differences in subclinical cardiovascular disease between African American and Caucasian women with systemic lupus erythematosus. Transl Res 2010; 153:51–59.
743. Scalzi L, Hollenbeak C, Wang L. Racial disparities for age at time of cardiovascular events and cardiovascular death in SLE patients. Arthritis Rheum 2011; 62:2767–2775.
744. Toloza SMA, Uribe G, Mcgwin G, Alarco GS, Fessler BJ, Bastian HM et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50:3947–3957.
745. Wang X-Y, Tang X-Q, Huang Y-J, Chen W-Y, Yu X-Q. Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Clin Rheumatol 2012; 31:669–675.
746. Zhang C, Lu L, Li F, Li H, Gu Y. Evaluation of Risk Factors That Contribute to High Prevalence of Premature Atherosclerosis in Chinese Premenopausal Systemic Lupus Erythematosus Patients. J Clin Rheumatol 2009; 15:111–116.
747. Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399–2406.
748. Asanuma Y, Oeser A. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2407–2415.
749. Rúa-Figueroa I, Arencibia-Mireles O, Elvira M, Erausquin C, Ojeda S, Francisco F et al. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 2010; 69:1136–1139.
750. Roldan C a, Joson J, Sharrar J, Qualls CR, Sibbitt WL. Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study. J Rheumatol 2010; 37:71–78.
751. Ghosh P, Kumar A, Kumar S, Aggarwal A, Sinha N, Misra R. Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. Clin Rheumatol 2009; 28:1259–1265.
752. Kiani AN, Fishman EK, Petri M. Aortic valve calcification in systemic lupus erythematosus. Lupus 2006; 15:873–876.
753. Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei G-Z et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther 2009; 11:R186.
754. McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol 2014; 66:130–139.
755. O’Neill SG, Pego-Reigosa JM, Hingorani AD, Bessant R, Isenberg D a, Rahman A. Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 2009; 48:573–575.
756. Bartoloni E, Alunno A, Bistoni O, Gerli R. Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy. Clin Rev Allergy Immunol 2013; 44:14–22.
757. American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11–66.
758. Elliott J, Manzi S, Edmundowicz D. The role of preventive cardiology in systemic lupus erythematosus. Curr Rheumatol Rep 2007; 9:125–130.
759. Urquizu-Padilla M, Balada E, Chacón P, Pérez EH, Vilardell-Tarrés M, Ordi-Ros J. Changes in lipid profile between flare and remission of patients with systemic lupus erythematosus: a prospective study. J Rheumatol 2009; 36:1639–1645.
760. Petri M, Pérez-Gutthann S, Spence D, Hochberg M. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93:513–519.
761. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10:359–364.
762. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WMM et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by re. Atherosclerosis 2012; 223:1–68.
763. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2889–2934.
764. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and T of HBC in A (Adult TPI. Third Report of the National Cholesterol Education Program (NCEO) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106:3143– 3421.
765. Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia. Rheumatology 2003; 42:758–762.
766. Magadmi MEL, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM et al. Hyperinsulinemia , Insulin Resistance , and Circulating Oxidized Low Density Lipoprotein in Women with Systemic Lupus Erythematosus Guidelines of The National Cholesterol Education Program. J Rheumatol 2006; 33:50–56.
767. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:2541–2549.
768. Olusi SO, George S. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vasc Health Risk Manag 2011; 7:75–80.
769. Hua X, Su J, Svenungsson E, Hurt-Camejo E, Jensen-Urstad K, Angelin B et al. Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease. Scand J Rheumatol 2009; 38:184–189.
770. Chung CP, Oeser A, Raggi P, Solus JF, Avalos I, Linton MF et al. Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clin Rheumatol 2008; 27:1227–1233.
771. Orlacchio A, Bruce IN, Rahman P, De TK, Bernardi G, George-hyslop PHS et al. The apolipoprotein E2 isoform is associated with accelerated onset of Coronary Artery Disease in Systemic Lupus Erythematosus. Med Sci Monit 2008; 14:233–238.
772. Vuilleumier N, Charbonney E, Fontao L, Álvarez M, Turck N, Sánchez J-C et al. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci 2008; 115:25–33.
773. Petri M, Spence D, Bone L, Hochberg M. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71:291–302.
774. Bruce I, Urowitz M, Gladman D, Hallett D. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26:2137–2143.
775. Leong K, Koh E, Feng P, Boey M. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1264–1267.
776. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849–1860.
777. Akdogan A, Kilic L, Akman U, Dogan I, Karadag O, Bilgen SA et al. Aspirin resistance in systemic lupus erythematosus . A pilot study. Lupus 2013; 22:835–838.
778. Avalos I, Chung CP, Oeser A, Milne GL, Borntrager H, Morrow JD et al. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Lupus 2007; 16:981–986.
779. Asherson RA, Baguley E, Pal C, Hughes GR V. Antiphospholipid syndrome: five up Ann Rheum Dis 1991; 80:805–810.
780. Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology 2014; 53:275–284.
781. Chan TM, Tse KC, Tang CSO, Lai KN, Li FK, Tang S. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 2005; 14:947–952.
782. Kitamura N, Matsukawa Y, Takei M, Sawada S. Antiproteinuric Effect of Angiotensinconverting Enzyme Inhibitors and an Angiotensin II Receptor Blocker in Patients with Lupus Nephritis. J Int Med Res 2009; 37:892–898.
783. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 1998; 24:423–456.
784. Yilmaz N, Aydin SZ, Inanc N, Karakurt S, Direskeneli H, Yavuz S. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients. Lupus 2012; 21:491–495.
785. Rúa-Figueroa I, Nóvoa J, García-laorden MI, Erausquin C, Castro FR De, Herrera-Ramos E et al. Clinical and immunogenetic factors associated with pneumonia in patients with systemic lupus erythematosus: a case-control study. J Rheumatol 2014; 41:1801–1807.
786. Conti F, Rezai S, Valesini G. Vaccination and rheumatic diseases: is there still a dilemma? Curr Rheumatol Rep 2007; 3:79–91.
787. Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule — United States , October 2005 – September 2006 QuickGuide. 2006; 54:1–4.
788. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70:414–422.
789. Van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheuma. Autoimmun Rev 2011; 10:341–352.
790. Bouza E, Moya J, Muñoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001; 15:335–361.
791. Klippel JH, Karsh J, Stahl NI, Decker JL, Steinberg AD. A controlled study of pneumococcal in polysaccharide vaccine systemic lupus erythematosus. Arthritis Rheum 1979; 22:1321–1325.
792. Lipnick R, Karsh J, Stahl N, Blackelder W, Schiffman G, Klippel J. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 1985; 12:1118–1121.
793. Jarrett M, Schiffman G, Barland P, Grayzel A. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. Arthritis Rheum 1980; 23:1287–1293.
794. McDonald E, Jarrett M, Schiffman G, Grayzel A. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984; 11:306–308.
795. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34:147–153.
796. Tarján P, Sipka S, Maro L, Nemes E, Lakos G, Gyimesi E et al. No short-term immunological effects of Pneumococcus vaccination in patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31:211–215.
797. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauek S et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41:1828–1834.
798. Elkayam O, Paran D, Burke M, Zakut V, Ben-Yitshak R, Litinsky I et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 2005; 38:493–496.
799. Bernatsky S, Clarke A, Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 2002; 4:351–358.
800. Gadalla SM, Amr S, Langenberg P, Baumgarten M, Davidson WF, Schairer C et al. Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer 2009; 100:817–821.
801. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin J-F, Petri M et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013; 42:130–135.
802. Liang J-A, Sun L-M, Yeh J-J, Lin W-Y, Chang S-N, Sung H-C et al. Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study. Rheumatol Int 2012; 32:773–778.
803. Kang KY, Kim HO, Yoon HS, Lee J, Lee WC, Ko H-J et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 2010; 29:381–388.
804. Klumb EM, Pinto AC, Jesus GR, Jr MA, Jascone L, Gayer CR et al. Are women with lupus at higher risk of HPV infection? Lupus 2010; 19:1485–1491.
805. Ognenovski V, Marder W, Somers E, Johnston C, JG F, Selvaggi S et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004; 31:1763–1767.
806. Anderson LA, Gadalla S, Morton LM, Landgren O, Warren JL, Berndt SI et al. Population-based study of autoinmmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2010; 125:398–405.
807. Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G et al. Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus: Results from a Single Center. Ann N Y Acad Sci 2007; 1108:76–82.
808. Bernatsky SR, Cooper GS, Mill C, Ramsey-goldman R, Clarke ANNE, Pineau CA. Cancer Screening in Patients with Systemic Lupus Erythematosus. J Rheumatol 2006; 33:45–49.
809. Yazdany J, Tonner C, Trupin L, Panopalis P, Gillis JZ, Hersh AO et al. Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study. Arthritis Res Ther 2010; 12:R84.
810. Kipenm Y, Littlejohn G, Morand E. Methotrexate use in systemic lupus erythematosus. Lupus 1997; 6:385–389.
811. Sen D, Keen R. Osteoporosis in systemic lupus erythematosus: prevention and treatment Lupus 2001; 1:227–232.
812. Alele JD, Kamen DL, Hunt KJ, Ramsey-Goldman R. Bone geometry profiles in women with and without SLE. J Bone Miner Res 2011; 26:2719–2726.
813. Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol 2003; 22:318–323.
814. Houssiau FA, Lefebvre C, Depresseux G, Lambert M, Devogelaer J. Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol 1996; 35:244–247.
815. Jacobs J, Korswagen L, Schilder a M, van Tuyl LH, Dijkmans B a C, Lems WF et al. Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int 2013; 24:1827–1833.
816. Korczowska I, Olewicz-gawlik A, Hrycaj P, Lacki J. The Effect of Long-term Glucocorticoids on Bone Metabolism in Systemic Lupus Erythematosus Patients: The Prevalence of Its Anti-inflammatory Action upon Bone Resorption. Yale J Biol Med 2003; 76:45–54.
817. Tang XL, Griffith JF, Qin L, Hung VW, Kwok a W, Zhu TY et al. SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. Lupus 2013; 22:1162–1168.
818. Tang XL, Zhu TY, Hung VW, Qin L, Wong C-K, Kun EW et al. Increased organ damage associated with deterioration in volumetric bone density and bone microarchitecture in patients with systemic lupus erythematosus on longterm glucocorticoid therapy. J Rheumatol 2012; 39:1955–1963.
819. Mak A, Lim JQ, Liu Y, Cheak AA, Ho RC. Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals. Rheumatol Int 2013; 33:299–307.
820. Lee JJY, Aghdassi E, Cheung AM, Morrison S, Cymet A, Peeva V et al. Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus. J Rheumatol 2012; 39:1378–1384.
821. Gutiérrez-Polo R. Glucocorticoid induced osteoporosis. An Sist Sanit Navar 2003; 26:63–80.
822. Boling EF. Secondary Osteoporosis: for Glucocorticoid-Induced Underlying Disease Osteoporosis and the Risk. Clin Ther 2004; 26:1–14.
823. Devogelaer J-P, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J et al. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology (Oxford) 2013; 52:1058–69.
824. Yeap SS, Fauzi AR, Kong NCT, Halim AG, Soehardy Z, Rahimah I et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol 2008; 35:2344–7.
825. Gourlay M, Franceschini N, Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol 2007; 26:144–53.
826. Lambrinoudaki I, Chan D, Lau C, Wong R, Yeung S, Kung A. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27:1759–1765.
827. Mok CC, To CH, Mak A, Ma KM. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum 2005; 52:3997–4002.
828. Kung AWC, Chan TM, Lau CS, Wong RWS, Yeung SSC. Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology 1999; 38:1239–1244.
829. Nzeusseu A, Depresseux G. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus 2005; 14:517–520.
830. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62:1515–26.
831. Pérez Edo L, Alonso Ruiz A, Roig Vilaseca D, García Vadillo A, Guañabens Gay N, Peris P et al. [2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis]. Reumatol Clin 2015; 7:357–79.
832. Donabedian A. Explorations in Quality Assessment and Monitoring. In: Ann Arbor M (ed). The Definition of Quality and Approaches to Its Assessment. Vol 1. Health Administration Press, 1980.
833. Lahita R, Tsokos G, Buyon J, Koike T. Systemic Lupus Erythematosus. 5th Editio. Elsevier: San Diego, CA (USA), 2011.
834. Wallace DJ, Hahn BH. Dubois’ Lupus Erythematosus. 8th editio. Lippincott Williams & Wilkins: Philadelphia, PA (USA), 2002.
835. Khamashta M, Vilardell M. Lupus eritematoso sistémico. Caduceo Multimedia: Barcelona (España), 2009.
836. Frutos M, Martín-Gómez A, Toledo Rojas R. Nefritis lupica. In:Hernando L (ed). Nefrología Clínica. Ed. Panamericana, 2009, pp 474–483.
837. Schwartz MM, Korbet SM, Lewis EJ. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008; 23:1298–306.
838. Mackie BS, Mackie LE. Historical perspective. The PABA story. Australas J Dermatol 1999; 40:51–53.
839. Kullavanijaya P, Lim HW. Photoprotection. J Am Acad Dermatol 2005; 52:937–58.
840. Palm M, O´Donogue M. Update on photoprotection. Dermatol Ther 2007; 20:360–376.
841. Fourtanier A, Moyal D, Seité S. Sunscreens containing the broad-spectrum UVA absorber, Mexoryl® SX, prevent the cutaneous detrimental effects of UV exposure: a review of clinical study results. Photodermatol Photoimmunol Photomed 2008; 24:164– 174.
842. Pinnell S, Fairhurst D. Microfine zinc oxide is a superior sunscreen ingredient to microfine titanium dioxide. Dermatologic Surg 2000; 26:309–314.
843. Moseley H, Cameron H, Leod TM, Clark C, Dawe R, Ferguson J. New sunscreens confer improved protection for photosensitive patients in the blue light region. Br J Dermatol 2001; 145:789–794.
844. Schroeder P, Krutmann J. What is Needed for a Sunscreen to Provide Complete Protection. Skin Therapy Lett 2010; 15:4–5.
845. Ministerio de Sanidad y Consumo. Guía de Protección Solar. Dale años a tu vida. 2003.
846. Edlich R, Winters K, Lim H, Cox M, Becker D, Horowitz J et al. Photoprotection by sunscreens with topical antioxidants and systemic antioxidants to reduce sun exposure. J Long Term Eff Med Implants 2004; 14:317–340.
847. Darvay A, White I. Photoallergic contact dermatitis is uncommon. Br J Dermatol 2001; 145:597–601.
848. Hexsel CL, Bangert SD, Hebert A a, Lim HW. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products. J Am Acad Dermatol 2008; 59:316–323.
849. Therapeutic Goods Administration, Departament of Health and Ageing AG. A review of the scientific literature on the safety of nanoparticulate titanium dioxide or zinc oxide in sunscreens. knownano.org. 2006.
850. Holick MF. Vitamin D: A millenium perspective. J Cell Biochem 2003; 88:296–307.
851. Farrerons J, Barnadas M. Clinically prescribed sunscreen (sun protection factor 15) does not decrease serum vitamin D concentration sufficiently either to induce changes in parathyroid. Br J Dermatol 1998; 139:422–427.
852. Norval M, Wulf HC. Does chronic sunscreen use reduce vitamin D production to insufficient levels? Br J Dermatol 2009; 161:732–736.
853. American Academy of Dermatology and AAD Association. Position statement on Vitamin D. 2009; 25:1–4.
854. Valencia I, Kerdel F. Corticosteroides tópicos. In: Fitzpatrick (ed). Dermatología En Medicina General. Editorial Médica Panamericana, 2014, pp 2102–2106.